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CD4+ T cells are a critical component of the adaptive immune system as they generate large 
amounts of cytokines that help shape the immune milieu.   Additionally, they are the primary 
contributors to the immunopathology exhibited in Type 1 Diabetes.  The field of 
immunometabolism has elucidated that the cellular metabolic profile of immune cells has a 
significant impact on their function, and ultimately the fate of the overall response.  Naïve CD4+ 
T cells rely primarily on mitochondrial oxidative phosphorylation, but upon antigen encounter, 
reprogram their metabolism to aerobic glycolysis.  Understanding the mechanisms that govern 
these programs could be critical in developing new therapies for limiting aberrant T cell 
responses in autoimmunity.  Here we examined the contributions of two different molecules, 
Lymphocyte Activation Gene 3 (LAG-3) and reactive oxygen species (ROS) in controlling T cell 
metabolism.  LAG-3 is an inhibitory receptor expressed on the surface of CD4+ T cells, and 
deficiency in naïve T cells leads to enhanced homeostatic expansion.  Our results indicate that 
LAG-3 expression on naïve CD4+ T cells serves to restrain cellular metabolism and 
mitochondrial biogenesis as a means of maintaining quiescence.  These results are compelling as 
loss of LAG-3 expression in a model of Type 1 Diabetes results in accelerated disease 
progression, potentially due to T cell metabolic enhancements, as our data would suggest.  Single 
nucleotide polymorphisms in the LAG-3 gene have also been linked to autoimmune disease 
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susceptibility.  With regards to ROS, Type 1 Diabetes is known to be highly driven by oxidative 
stress, and CD4+ T cells require acute doses of ROS to drive optimal activation.  Therefore, we 
sought to understand if ROS signaling contributes to the metabolic transition that occurs during 
T cell activation.  Indeed, ROS inhibition resulted in reduced mTOR signaling and aerobic 
glycolysis.  Altering metabolism in this manner also delayed Type 1 Diabetes progression in an 
adoptive transfer model of disease.  Collectively, this work demonstrates that both LAG-3 and 
ROS regulate CD4+ T cell metabolism, which, in turn, greatly impacts T cell activation potential 
and ability to drive disease.   
  vii 
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PREFACE 
 
“Don’t give up, don’t ever give up.” 
 
- Coach James “Jimmy V” Valvano 
 
Growing up in the Previte household, sports were always a constant, whether it was cheering on 
a Pittsburgh sports team or watching the sheer excitement of March Madness.  This quote by 
Coach Valvano has always been one that resonated with me, as it was so poignant given his 
unwavering optimism and courage in the face of cancer.  Graduate school has been quite the 
rollercoaster ride, and there were many times where giving up would have been easier than 
staying the course.  However, along with this quote, some very special people helped me to 
persevere and finally reach my goal. 
 First I would like to thank Dr. Jon Piganelli for taking a chance on me, and allowing me 
to join his laboratory.  You have allowed me to learn and think on my own and gave me the 
reigns to drive this work myself.  For that I am truly grateful.  I hope you feel that the gamble 
paid off.  To the Piganelli lab members, both past and present, thank you for all the help and 
laughter along the way, especially when things were not working scientifically.  Specifically, I 
would to thank Drs. Gina Coudriet and Meghan Marre.  You ladies have helped me so much in 
navigating my way through graduate school with your wisdom and experience.  Also, you have 
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been excellent examples of women scientists and mothers.  I am so proud to not only call you my 
colleagues, but also my friends. 
 To my wonderful grandparents, Martin and Margaret Sholtis, and Peter and Imogene 
Previte, for instilling in me that a strong work ethic can help you achieve your goals.  They 
worked hard to provide better lives for their children and grandchildren, and it is through their 
drive and determination that I have been blessed with the opportunities I have had.  Moreover, 
they taught me the importance of education, and were always a source of unconditional love.  
Sadly, I lost two of my grandparents during this process, and my only regret is that they are not 
here today to see this dream come to fruition.   
 To my sister, Marissa Previte, thank you for being my roommate, running partner, and 
fellow Housewives lover.  It has been great growing into adulthood with you over the past five 
years, and you have been a great source of levity, love, and fun.  I am proud of how close we 
have become.   
 Next, I would like to thank my parents, Mark and Laverne Previte.  Thank you, Mom, for 
being the glue that holds this family together.  Your strength and love are unmatched by anyone I 
know.  Growing up, you showed me that a woman can be a successful professional, mother, and 
wife, and I could not have asked for a better female role model.  I hope I can be at least half as 
successful as you have been.  To my dad, the first Dr. Previte – thank you for paving the way for 
me in academia, but also allowing me to blaze my own trail into science.  I can honestly say that 
you were the first person to teach me how to think critically, whether that was discussing 
politics, curriculum, or zone versus man-to-man defense.  I cannot thank both of you enough for 
being constant sources of love and support. 
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 To my wonderful husband, Dr. Matthew Brown.  I do not think any of this would have 
been possible without you.  You have seen me at my best and my worst, and have loved and 
supported me regardless.  You are one of the most driven and intelligent people I have ever met, 
and I am so lucky to have you.  Thinking back, I am so thankful for that first BGSA happy hour 
where we met, and I look forward to what the future holds for us.  I love you so much.   
 Lastly, I would like to end with this: 
“…And to all the little girls who are watching this, never doubt that you are valuable and 
powerful and deserving of every chance and opportunity in the world to pursue and 
achieve your own dreams." 
  
--Hillary Rodham Clinton 
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1.0  INTRODUCTION 
1.1 TYPE 1 DIABETES 
The immune system protects against pathogens, in part by distinguishing self from non-self.  
While this self/non-self recognition is usually maintained, in some instances the immune system 
can mount a response against self-antigens, leading to organ-specific autoimmunity.  Tolerogenic 
mechanisms, including T regulatory cells, are in place to combat ensuing autoimmunity; 
however, these mechanisms can fail due to inherent dysfunction or unrestrainable inflammation.  
This subsequent autoimmune attack is responsible for numerous diseases including rheumatoid 
arthritis, multiple sclerosis, and type 1 diabetes, to name a few.   
Specifically, type 1 diabetes (T1D) occurs when autoreactive T cells target pancreatic β 
cells for destruction.  The loss of β cell mass and function results in reduced insulin secretion and 
diminished blood glucose regulation, culminating in hyperglycemia.  By the time T1D patients 
present with hyperglycemia, 80-90% of the β cell mass has already been lost [1, 2].  Therefore, 
in order to maintain blood glucose levels, patients must administer exogenous insulin for the 
remainder of their lives.  If poorly controlled, hyperglycemia can lead to multiple complications 
including cardiovascular issues, nephropathy, and retinopathy, to name a few. While insulin 
therapy is efficacious for most, there are a percentage of patients who cannot manage blood 
glucose with insulin alone, and islet transplantation has become a potential therapy for these 
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patients [3].  However, with transplantation, patients must be placed on rigorous 
immunosuppressive regimens to minimize islet graft rejection, and several of these therapies 
have been shown to have direct negative effects on β cells [4, 5].  
CD4+ and CD8+ T cells contribute to the immunopathology exhibited in T1D and 
demonstrate islet infiltration [6-8].  Additionally, activated T cells mediate auto-autoantibody 
secretion by B cells [9, 10], further targeting islet β cells.  While the initiating events that trigger 
immune activation against the β cell are not fully elucidated, it is well accepted that genetic and 
environmental factors may be responsible for promoting the initial break in tolerance.  These 
factors include: viral infection [11], family history [12], ER stress [13, 14], chemical exposure 
[15], and pancreatic inflammation and ROS [16].  
The most widely used animal model of T1D is the non-obese diabetic or NOD mouse, 
that spontaneously develops the disease, closely mimicking human progression [17-20]. With 
regards to T cell biology, the NOD.BDC-2.5 T cell receptor (TCR) transgenic animal has been 
most critical in further dissecting antigen-specific T cell responses relevant to T1D [21-23].  
Here, all CD4+ T cells recognize a peptide formed by covalent cross-linking of two β cell 
peptides:  proinsulin and Chromogranin A (CHgA) [24].  Adoptive transfer of isolated BDC-2.5 
T cells into NOD.scid recipients is sufficient for T1D induction; yet, very rarely do BDC-2.5 
mice demonstrate T1D incidence themselves, owed to an inherent regulatory T cell population 
[25, 26].   
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1.2 METABOLIC PATHWAYS UTILIZED IN T CELLS 
With the recent interest in immune cell metabolism, it has become better appreciated that cellular 
metabolic pathways are a contributing factor in dictating T cell function and fate.  As the 
functions of naïve, effector, and memory T cells differ, so do their nutrient requirements, 
resulting in differential bioenergetic profiles.  Two predominant metabolic pathways utilized by 
T cells are glycolysis and oxidative phosphorylation (OXPHOS) (Figure 1).  Glycolysis is the 
breakdown of glucose to generate ATP and reducing equivalents that maintain cellular redox 
balance.  Once glucose is transported into the cell, it undergoes multiple enzymatic reactions that 
ultimately result in the formation of two pyruvate molecules for each molecule of glucose [27].  
At that point, the presence of oxygen dictates the fate of pyruvate.  If oxygen is present, pyruvate 
will move into the mitochondria to support oxidative metabolism.  Alternatively, in the absence 
of oxygen, pyruvate is converted to lactate that is secreted by the cell in a process known as 
anaerobic glycolysis [27, 28].  However, there are instances in which glucose is converted to 
lactate even in the presence of oxygen [27, 29-31].  This process, known as aerobic glycolysis, or 
the Warburg effect, is demonstrated by activated T cells [32-34].   
If pyruvate is transported into the mitochondria, it is converted to acetyl-CoA and enters 
the tricarboxylic acid (TCA) cycle [28, 35].  Here, a series of chemical reactions occur that result 
in the production of more energy (ATP), reduction of NAD+ to NADH, and release of carbon 
dioxide [36].  Glucose is not the only carbon source that can be utilized for acetyl-CoA 
generation and metabolism, as fatty acids and glutamine can also be shuttled into the TCA cycle.   
The NADH produced by the TCA cycle is used to support the electron transport chain 
(ETC), also located in the mitochondria, thus coupling respiration with ATP synthesis [37].  The 
ETC is comprised of five mitochondrial proteins, complexes I-V, that drive electron movement 
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via redox reactions [35, 38, 39].  In addition, protons (H+) are translocated from the 
mitochondrial matrix to the intermembrane space, creating a concentration gradient.  Complex 
V, or ATP synthase, serves as a proton pump, moving protons down the concentration gradient 
back into the matrix, driving phosphorylation of ADP to ATP [40-42].  Oxygen serves as the 
final electron acceptor in the ETC generating superoxide (O2-), and is thus consumed by the 
process.  Superoxide cannot easily cross membrane barriers; therefore, mitochondrial-expressed 
manganese superoxide dismutase (MnSOD) acts to dissipate superoxide to hydrogen peroxide 
(H2O2) as a means of eliminating the species [43, 44].  Alternatively, hydrogen peroxide is easily 
diffusible across membranes, and mitochondrial glutathione peroxidase and cytoplasmic catalase 
facilitate the decomposition of hydrogen peroxide to water and oxygen (O2) [45].  These 
enzymes together serve as a means of protecting the cell against free radical damage.   
Work in tumor and T cell biology have elucidated that aerobic glycolysis is the preferred 
pathway for highly proliferative cells [30, 31, 46].  This is in part due to glycolysis shuttling 
carbon molecules towards biosynthetic pathways that enable lipid membrane and nucleotide 
formation.  Phosphorylated glucose (Glucose-6-phosphate) can either be shuttled through 
glycolysis or into the Pentose Phosphate Pathway (PPP), which aids in nucleotide synthesis 
(Figure 1) [47].  Additionally, citrate can be shuttled out of the TCA cycle to build lipids [27, 
28].  Both metabolic shunts are upregulated in activated T cells to support daughter cell 
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Figure 1.  Metabolic Pathways in T cells. 
T cells have been shown to utilize various metabolic pathways to generate ATP, drive proliferation, balance cellular 
redox or maintain longevity.  Glycolysis and the Pentose Phosphate Pathway (PPP) take place in the cytosol, while β 
oxidation (Fatty Acid Oxidation) and glutaminolysis feed directly into the Tricarboxylic Acid Cycle (TCA) that 
occurs in the mitochondria.  The Electron Transport Chain (ETC) also occurs in the mitochondria, resulting in ATP 
formation and oxygen consumption.     
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1.3 NAÏVE T CELLS 
1.3.1 Actively maintained quiescence 
Following development in the thymus, naïve T cells constantly traffic through the lymphatics as 
a means of immune surveillance.  Therefore, naïve T cells must generate enough ATP to power 
cytoskeletal rearrangement for migration.  To do so, they rely on oxidative metabolism, which 
provides maximal ATP production from nutrients such as glucose, glutamine, and fatty acids 
[48-50].  Naïve T cells are considered relatively quiescent as they demonstrate very low levels of 
homeostatic proliferation [51, 52].  With this, their biosynthetic needs are greatly reduced 
compared to actively proliferating cells, which is reflected in their considerably lower levels of 
glycolysis [48-50].   
Studies examining naïve T cell quiescence have elucidated that it is a much more active 
process, rather than simply a default state [53].  Quiescence is dynamically preserved by a 
transcriptional program that not only upregulates quiescence-associated genes, but 
simultaneously inhibits activation genes. The FOXO (Forkhead box O) family of transcription 
factors are highly active in naïve T cells and other quiescent cell types, and regulate pathways 
associated with proliferation, apoptosis, and metabolism [54, 55].  With regard to proliferation, 
FOXOs stabilize expression of cell cycle inhibitors, including p27 and p21 [54, 55].  FOXO1 
specifically enhances expression of Kruppel-Like Factors (KLFs), another family of quiescence 
regulators.  In particular, LKLF is known to suppress Myc expression in T cells to control 
metabolism and cell cycle entry [56].  KLFs also promote expression of multiple homing 
molecules, including CD62L, which are necessary for T cell lymphatic trafficking [57].  More 
recently, Tsc1 (Tuberous sclerosis 1), a known tumor suppressor, was shown to actively suppress 
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mammalian target of rapamycin (mTOR) signaling in naïve T cells as a means of preserving 
quiescence [58].  Interestingly, loss of Tsc1 resulted in increased apoptosis of peripheral naïve T 
cells and defective antigen-specific responses in vivo [58].  This work highlights that alterations 
in T cell homeostasis can have dramatic effects on activation potential and antigen clearance.    
 Low-level T cell receptor (TCR) stimulation by self-peptides presented by major 
histocompatibility complex (MHC), or tonic signaling, is necessary for protection against 
apoptosis as TCR blockade during this process results in holes in the T cell repertoire [59-61]. T 
cells deficient in TCR signaling components like Fyn and Lck, demonstrated reduced survival 
[62-64], suggesting that the signals required by naïve T cells mimic those used to promote 
activation.  Microarray studies comparing tonic signals to those from foreign antigens revealed 
similar gene expression profiles induced by both self and antigenic peptides [65]; however, the 
degree of induction was much lower in self-stimulated T cells.  These results suggest that 
signaling to maintain homeostasis versus induce activation are the same, but it is the strength of 
signal that ultimately determines T cell fate. 
 
1.3.2 Interleukin-7  
As with all immune cells, growth factors and signaling are necessary for maintaining the immune 
system.  For naïve T cells, Interleukin-7 (IL-7) plays a significant role in sustaining homeostasis 
and cellular metabolism [66-68].  IL-7 is produced by various non-hematopoietic cells including 
thymic epithelial cells, lymphatic endothelial cells [69], and fibroblastic reticular cells [70, 71].  
IL-7 signals via the IL-7 receptor which is composed of the common γ chain subunit CD132 and 
the unique IL-7Rα (CD127) subunit.  Global deletion of the IL-7R results in a severe combined 
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immunodeficiency (SCID) phenotype, further highlighting its requirement in T cell survival [72-
74].  IL-7 promotes naïve T cell survival and population maintenance by mediating expression of 
the anti-apoptotic proteins, Bcl-2 [73, 75] and Mcl-1 [76], while simultaneously reducing 
expression of pro-apoptotic proteins Bid, Bim, and Bad [52, 77, 78].  IL-7 has been shown to be 
a critical growth factor for developing thymoctyes [79] and memory T cells [80-82] as well.  
IL-7/IL-7R signaling is mediated by downstream activation of the JAK3/STAT5 and 
PI3K/Akt signaling pathways [68, 79].  Activation of STAT5 and Akt by phosphorylation leads 
to increased survival and glucose metabolism in naïve T cells [83, 84].  In several instances 
increased IL-7 signaling results in downregulation of surface and mRNA expression of IL-7R, 
suggesting a negative feedback loop to protect against over stimulation and breaks in quiescence 
[85].  This downregulation has also been suggested as a mechanism to prevent overutilization by 
specific T cell clones, resulting in atrophy of others, and thus creating a less diverse T cell 
population.   
The PI3/Akt pathway regulates FOXO transcription factors via phosphorylation, resulting 
in translocation from the nucleus to the cytoplasm.  Nuclear localization of FOXOs drives 
expression of the cell cycle inhibitors like p27 Kip1.  Thus, inhibition of FOXOs by Akt via IL-7 
signaling can lead to cell cycle entry and proliferation.  The phosphatase PTEN regulates Akt 
activation [86] and is highly expressed in quiescent cells, including hematopoietic stem cells [87, 
88] and naïve T cells [89].  PTEN-deficient T cells demonstrate extensive hyperproliferation and 
do not require IL-7 to maintain either proliferation or survival, due to constitutively active Akt 
[89, 90].     
Expression and surface trafficking of the passive glucose transporter 1 (Glut1), which is 
essential for glucose uptake in T cells, increases upon IL-7 signaling, and knockdown of either 
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STAT5 or Akt reduces this response [68].  Interestingly, in vitro experiments where T cells were 
cultured in high or low glucose demonstrated that glucose concentration correlated with the 
degree of responsiveness to IL-7, indicating that glucose uptake aids in perpetuating IL-7 
signaling [68].  The development of conditional deletion of the IL-7R in T cells allowed for 
further understanding of how IL-7 regulates naïve T cell metabolism and survival in vivo [91].  
These studies indicated that loss of IL-7 signaling led to decreased cell size and frequency of 
both CD4+ and CD8+ T cells, which was due to reduced pSTAT5 signaling, glucose uptake, and 
cellular glycolysis [91].  While the main role of IL-7 is to maintain glycolysis in naïve T cells, 
there is some evidence that it also supports amino acid transport in CD8+ T cells, which is 
necessary for T cell growth [92].  
 
1.3.3 Homeostatic proliferation of naïve T cells 
Naïve T cells are successful at maintaining steady numbers in the periphery.  This sense of space 
is controlled by competition for survival signals from self-peptide/MHC and IL-7.  Yet, low 
levels of homeostatic proliferation of naïve T cells do occur.  Due to the utilization of IL-7 in the 
periphery, levels of this cytokine in lymphoreplete animals remain quite low [93].  During 
instances of lymphopenia, serum IL-7 levels increase due to lack of utilization, and can therefore 
trigger homeostatic expansion of the remaining T cells.  This is exemplified by robust 
proliferative responses of naïve T cells adoptively transferred into Rag-deficient animals, 
whereas transfer into wildtype syngeneic animals results in very low, if any, proliferation.  
Several surface markers have been reported to alter homeostatic expansion such as CD24, which 
is necessary for proliferation [94] and B and T lymphocyte attenuator (BTLA) which inhibits 
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proliferative potential [95].  CD5 has also been identified as a marker of increased tonic 
signaling and proliferation on naïve T cells [96, 97] 
Work by Min et al. further identified two different types of proliferative responses that 
occur upon T cell transfer into lymphopenic hosts. The slower, more limited proliferation was 
termed homeostatic, which was shown to be highly dependent upon IL-7 [98].  Alternatively, 
some T cells underwent more vigorous, IL-7-independent expansion, termed spontaneous [98].  
These spontaneously proliferative T cells, while naïve in the sense that they have not 
experienced foreign antigen, demonstrated memory-like characteristics, including increased 
CD44 expression and a lowered activation threshold [99, 100].    
1.4 T CELL ACTIVATION AND METABOLIC REPROGRAMMING 
Upon TCR:peptide/MHC (Major histocompatibility) engagement, naïve T cells become 
activated, and with activation different functions ensue, including clonal expansion and effector 
function acquisition.  With these new functions, the cellular metabolic profile of T cells also 
drastically changes [48, 49, 101].  Cellular division is an energetically demanding process, as the 
cell must replicate DNA and build new plasma membranes.  To support the heightened level of 
macromolecule synthesis and ATP demand, T cells must transition from a slower, oxidative 
metabolism, to a faster program heavily dependent upon aerobic glycolysis (Figure 2).  This 
metabolic transformation has been extensively characterized in tumor cells, and is often referred 
to as the “Warburg effect,” as it was first observed/described by Dr. Otto Warburg [31].  
  




















Figure 2.  T cell metabolic reprogramming during the transition from naïve to effector and effector to 
memory.   
Naive T cells are predominantly oxidative, breaking down glucose, fatty acids, and amino acids via the TCA cycle 
and electron transport chain.  Antigenic stimulation results in a transition to aerobic glycolysis, where glucose is 
metabolized to lactate or shuttled into biosynthetic pathways.  Contraction to a memory T cell population results in 
transition back to a more oxidative phenotype. 
 
 
The metabolic reprogramming of activated T cells can be broken down into two stages:  
1. cell growth and preparation for division, and 2. clonal expansion.  During the early stages of T 
cell activation, mitochondrial metabolism is critical for supporting cellular growth in preparation 
for division.  Specifically, calcium (Ca2+) signaling mediated by TCR engagement drives 
increased activation of the energy sensor AMP-activated protein kinase (AMPK) [102].  Once 
the requirements for cellular division have been met and division begins, aerobic glycolysis 
dominates.  It seems counterintuitive that aerobic glycolysis would be preferred as it only 
generates two net ATP, in comparison to the thirty-eight generated via OXPHOS.  However, as 
explained earlier, aerobic glycolysis results in increased carbon shuttling into the pentose 
phosphate pathway, which is responsible for lipid and nucleotide synthesis, along with 
production of reducing equivalents to maintain cellular redox balance.   
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1.4.1 T cell “Myc-tabolism” 
To support the new requirement for aerobic glycolysis, activated T cells undergo a major 
alteration in their transcriptome.  The transcription factor Myc has been well-characterized as an 
important mediator of this process.  Naïve T cells express little to no Myc; however, 24 hours 
post-stimulation, Myc expression levels are highly upregulated [103].  Signaling via the PI3/Akt 
and mTOR pathways enable this increased expression.  Myc induces expression of various 
glycolysis-supporting genes, including the glucose transporter Glut1, hexokinase 2 (HK2), and 
lactate dehydrogenase (LDHA) (Figure 3).  With this new metabolic machinery in place, 


























Figure 3.  Myc-dependent genes of glycolysis. 
The transcription factor Myc has been shown to upregulate expression of various glycolysis-associated genes 
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Myc is a key oncogene, and similar to its role in T cells, is able to drive high levels of 
glycolysis in tumors [30, 104].  In some instances, it has even been shown to result in glucose 
addiction [29].  Also in tumors, Myc has also been shown to support cell cycle progression, thus 
making it a key linchpin in coordinating rapid proliferation with the metabolic programming 
necessary to support it.  This is also true for T cells during activation.  Unlike tumors, activated T 
cells do not demonstrate sustained Myc expression.  As stated previously, levels of Myc reach a 
peak at 24 hours post-stimulation in T cells; however, T cells are able to maintain glycolysis well 
past this point.  A recent study by Chou et al. indicated that another transcription factor AP4, is 
upregulated during CD8+ T cell activation and maintains expression of glycolysis-associated 
genes following downregulation of Myc expression [105].  In their model, CD8+ T cells that 
lacked AP4 were unable to sustain expression of Myc-driven genes and glycolysis, resulting in 
reduced immunity against West Nile Virus [105].   
 Aerobic glycolysis is not the only metabolic pathway powered by Myc.  Myc has also 
been shown to increase expression of genes associated with the pentose phosphate pathway and 
glutaminolysis, both of which aid in increased macromolecule synthesis during T cell activation 
[103, 106, 107].  Interestingly, Myc has also been shown to drive increased OXPHOS and 
mitochondrial biogenesis in some cell types [108-110]; yet, it remains to be determined if this is 
true in T cells.    
 
1.4.2 Glutamine – a key amino acid during activation  
While aerobic glycolysis is the predominant pathway utilized in effector T cells, oxidation via 
the mitochondria is not completely terminated.  Some pyruvate generated via glycolysis does 
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translocate into the mitochondria for oxidation via the TCA cycle and electron transport chain, 
resulting in ATP production and ROS generation.  In addition, uptake and oxidation of the amino 
acid glutamine via glutaminolysis is highly upregulated in activated T cells, indicating that 
glucose is not the only energy source required by activated T cells [46, 50]. Glutamine 
metabolism supports ATP generation, redox regulation, and TCA cycle intermediate restoration 
[46, 49].  Transport of glutamine into the T cell occurs in large part via the Alanine-Serine-
Cysteine transporter 2 (ASCT2) [111], but use of the sodium-coupled neutral amino acid 
transporters (SNAT) 1 and 2 can also facilitate glutamine uptake [112, 113].  Upregulation of 
ASCT2 and thus increased glutamine uptake is highly dependent upon CD28 signaling [111, 
112].  Once in the cell, glutamine is rapidly converted to glutamate by the enzyme glutaminase.  
Glutamate can then be utilized for lipid, purine, and pyrimidine synthesis, enabling cell 
membrane formation and DNA replication.  Additionally, in conjunction with cysteine and 
glycine, glutathione is produced, which is critical for maintaining cellular redox balance, 
especially with increased ROS being generated via increased OXPHOS [114].   
Studies have indicated that the requirement for glutamine occurs in the later stages of T 
cell activation, primarily to support proliferation and cytokine production.  Depriving T cells of 
glutamine during activation resulted in reduced Interferon-γ (IFNγ) and Interleukin-2 (IL-2) 
production [112, 115, 116].  Also, the concentration of glutamine present during T cell activation 
in vitro was directly proportional to the degree of proliferation observed [112, 115].  Glutamine 
concentration had no effect on CD69 expression on T cells following stimulation with αCD3, but 
did modulate CD25 upregulation in the same cells, again highlighting its requirement for 
proliferation and not for activation [115].     
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Further studies have demonstrated that the upregulation of these metabolic pathways 
during T cell activation is a highly-coordinated event.  For example, not only is Myc critical for 
driving expression of glycolytic genes, but it also mediates transcription of glutamine 
transporters and glutaminolytic enzymes [103, 117].  Moreover, the inhibition of the anaphase-
promoting complex-cyclosome (APC/C)-Cdh1 during T cell activation allows for upregulation 
of both 6-phosphofructo-2-kinase/fructose-2,6- biphosphatase 3 (PFKFB3) and glutaminase, 
each rate limiting enzymes of glycolysis and glutaminolysis, respectively [118].  This 
upregulation correlated with increased T cell movement into S phase of the cell cycle, further 
delineated the interplay between cellular proliferation and metabolism.        
  
1.4.3 T cell asymmetric division and metabolism 
Asymmetric division is a process whereby two phenotypically different daughter cells result 
from a single mitotic event.  This process has been demonstrated not only by mammalian cells, 
but also those from Drosophila and C. elegans [119].  In particular, stem cells are the most well 
studied cells that demonstrate these properties.  With stem cells, this mechanism is in place to 
ensure self-renewal of a pluripotent progenitor while also providing a cell for terminal 
differentiation [120].  During activation, T cells have shown similar asymmetric division [121-
124].  Following APC encounter, the T cell divides for the first time, with the proximal daughter 
demonstrating a more effector-like phenotype (CD62Llo, CD25hi, CD44hi, CD69hi, IFNγhi), while 
the distal daughter exhibits memory T cell characteristics (CD62Lhi, CD25lo, CD44lo, CD69lo) 
[123].  Adoptive transfer experiments indicated that both proximal and distal daughters provided 
protection against an acute infection directly after transfer.  However, distal daughters provided 
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more robust protection during a secondary challenge 30 days post-transfer, further solidifying 
their memory potential [123].  TCR affinity has been shown to influence asymmetry as T cell 
stimulation with more antigenic peptides results in more distinct asymmetric populations [125].  
With regards to disease potential, CD8hi proximal daughters showed increased diabetogenicity 
and immunopathology in a Rip-mOVA model of Type 1 diabetes (T1D) [125].    
More recently metabolism and mTOR signaling were shown to be segregated 
asymmetrically during T cell division [126, 127].  Verbist et al. reported that APC proximal T 
cells expressed higher levels of Myc and were more glycolytic in comparison to distal daughters 
[127].  These results corroborated studies performed by Pollizzi et al., which indicated that 
mTOR and its signaling are inherited asymmetrically as well, with CD8hi mTORhi T cells 
demonstrating greater size and glycolytic capacity [126].  Interestingly, both studies indicated 
that CD8hi T effectors and CD8lo memory precursors showed no difference in mitochondrial 
respiration, suggesting that the enhanced oxidative potential memory cells exhibit [128-130] may 
require further shaping by extrinsic factors, like Interleukin-15 (IL-15) [131].  It is important to 
note that this is certainly not the only way in which memory T cells are formed, but may explain 
differences between central memory (those from asymmetric division) versus effector memory 
(those generated during effector contraction).   
1.5 MEMORY T CELLS AND FATTY ACID OXIDATION 
Following antigen clearance, T effector cells undergo one of two fates – apoptosis or transition to 
a long-lived memory T cell (Tmem) [132-134].  Cellular metabolism has been shown to be a 
crucial factor in mediating the transition from effector to memory, in that T cells must transition 
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from aerobic glycolysis back to a more oxidative phenotype [50, 107, 130, 135, 136].  
Specifically, fatty acid oxidation via the mitochondria is the predominant pathway utilized by 
Tmem cells, and inhibition of this pathway drastically reduces the Tmem cell pools [129, 130, 136].  
To understand why fatty acid oxidation would be advantageous, one must consider the 
characteristics of a Tmem cell.  First, memory T cells must be long-lived, as their primary function 
is to protect against potential secondary antigen challenge [137].  With this comes the 
responsibility of maintaining basal processes that require ATP.  Fatty acid oxidation, in contrast 
to aerobic glycolysis, generates more ATP per molecule of substrate, thus providing the cell with 
more energy to power basal processes.  As stated earlier, aerobic glycolysis is important for 
shuttling carbons towards macromolecule synthesis, but as memory T cells do not rapidly 
proliferate, biosynthesis is less of a concern.  With secondary challenge, memory T cells mount a 
faster and more robust response in comparison to naïve T cells.  Since the propensity for 
activation is tightly coupled to cellular metabolism, memory T cells require a bioenergetic 
advantage over naïve T cells to support this functionality [128, 129].  
The bioenergetic advantage exhibited by memory T cells has been well characterized 
over the last several years.  This advantage includes increased mitochondrial biogenesis and 
mitochondrial mass, allowing for greater ATP production.  Additionally, Tmem possess a greater 
mitochondrial spare respiratory capacity (SRC) [128].  Most cell types only respire at a basal 
rate, which is considered only a fraction of their actual metabolic potential.  The SRC is the 
difference between the maximal, or the highest possible rate of oxygen consumption during 
cellular stress, and its basal rate.  CD8+ memory T cells have demonstrated enhanced SRC in 
comparison to both naïve and effector T cells, and this characteristic is highly dependent on fatty 
acid oxidation as treatment with the fatty acid oxidation inhibitor etomoxir results in decreased 
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SRC magnitude [128].  As IL-7 is necessary for survival and metabolism of naïve T cells, 
memory T cells rely heavily upon IL-15, another member of the common γ chain cytokine 
family.  Through in vitro and in vivo analyses, IL-15 is necessary for driving increased fatty acid 
oxidation, SRC, and mitochondrial biogenesis in memory T cells. 
 
1.6 LYMPHOCYE ACTIVATION GENE-3 
1.6.1 LAG-3 as a CD4 homolog 
Lymphocyte activation gene 3 (LAG-3; CD223), is a 70kDa type I transmembrane protein 
expressed by various immune cells, including CD8+ and CD4+ T cells [138, 139], T regulatory 
cells [140, 141], B cells [142], NK cells [138], and dendritic cells [143].  Structurally, LAG-3 
consists of four extracellular Ig domains, a connecting peptide region, a transmembrane domain, 
and a cytosolic tail [144, 145].  LAG-3 is considered a CD4 homolog, as they both share four Ig 
domains, yet there is only about 20% amino acid homology between the two proteins.  CD4 and 
LAG-3 share the common ligand, MHC class II, which is predominantly expressed on antigen 
presenting cells (i.e. macrophages, dendritic cells).  While their ligand is shared, CD4 or LAG-3 
ligand engagement results in opposing positive or negative signaling, respectively.  LAG-3 binds 
to MHC class II with a much higher affinity as compared to CD4 and at a different site, 
suggesting ligand competition as one regulatory role for LAG-3 [146].  
 The genes encoding LAG-3 and CD4 are located adjacently on the human chromosome 
12 [139].  Both genes share similar intron positioning, including an intron located in the first 
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immunoglobulin superfamily domain.  This, coupled with the homologous structure suggests 
they were derived from a common ancestor [139, 147].  Whole organ genetic studies indicated 
that LAG-3 expression was limited to lymphoid organs in humans, with similar results in mice 
[147, 148].  Yet, in mice detectable levels of LAG-3 mRNA were also found in the brain [148] 
Low levels of LAG-3 are expressed on the surface of naïve T cells in comparison to the 
high surface expression of CD4 on T cells [149].  LAG-3 is mainly located in large intracellular 
stores located near the microtubule-organizing center, poising LAG-3 to be quickly trafficked to 
the T cell surface upon activation [149].  This trafficking has been shown to be dependent upon 
protein kinase C signaling [149, 150].  At the T cell surface, LAG-3 is localized to the 
immunological synapse, co-localizing in lipid rafts with the TCR and CD4 [149, 151].  
 
1.6.2 Inhibitory receptor role of LAG-3 in T cell activation 
CD4 and LAG-3 play opposing roles by mediating or dampening activation, respectively, during 
T cell activation.  In order for LAG-3 to inhibit T cell activation, it requires downstream 
signaling via its cytoplasmic tail, as ectopic expression of tailless LAG-3 in T cell hybridomas 
did not inhibit cellular proliferation as effectively as wildtype LAG-3 [145].  Located in the 
cytoplasmic tail is the KIEELE motif, which studies using site-directed mutagenesis determined 
was required for LAG-3’s inhibitory function [144, 145].  Interestingly, the exact downstream 
signaling has yet to be elucidated; however, some studies have indicated that cross-linkage of 
surface LAG-3 resulted in calcium flux inhibition during T cell activation [152].  
 Numerous studies have helped to elucidate the inhibitory role LAG-3 plays during T cell 
activation.  In these studies, LAG-3:MHC class II engagement during activation resulted in 
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decreased CD69 expression, clonal expansion, and IFNγ and IL-2 production in vitro using 
antigen specific and nonspecific models, including SEB and OVA.  Similar results were 
observed in vivo using infection and nominal antigen models.  Alternatively, blockade of LAG-3 
using monoclonal antibodies in vivo and in vitro reversed its inhibitory effects [151].  These 
studies were the first steps towards understanding the potential for targeting LAG-3 in human 
diseases like chronic viral infections and cancer, to restore functional T cell responses. While 
another inhibitory receptor, CTLA-4 was shown to modulate T cell signaling by blocking 
localization of signaling proteins to TCR-associated lipid rafts [153, 154], LAG-3 did not 
demonstrate similar effects [151].          
 While it might be inferred that the inhibitory effects of LAG-3 would only be 
demonstrated in CD4+ T cells, as they directly interact with its ligand MHC class II, studies have 
shown that LAG-3 expression does inhibit CD8+ T cell responses as well [151, 155, 156].  This 
begs the question as to whether LAG-3 ligation is absolutely required for T cell inhibition.  The 
fact that LAG-3 is only upregulated to the T cell surface during activation highlights its role in 
fine-tuning the immune response.  Furthermore, as LAG-3 inhibits clonal expansion and effector 
function, two processes that require T cell metabolic reprogramming, we postulate that LAG-3 
plays an important role in tempering this response to protect against apoptosis and preserve the 
Tmem pool.  
To more fully understand the role of LAG-3 in disease models and immune cell function, 
animal global and conditional knockouts have been developed.  Not only has LAG-3 been shown 
to inhibit activated T cell responses, but it also regulates naïve T cell homeostatic expansion.  
Workman et al. showed that LAG-3-/- animals demonstrate enhanced expansion of both naïve 
CD4+ and CD8+ T cells, as compared to their wildtype counterparts [157].  Additionally, LAG-3-
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deficient OT.II CD4+ T cells repopulated lymphopenic hosts to a greater extent following 
adoptive transfer [157].  LAG-3 has also been implicated as a negative regulator in several 
autoimmune disease models.  For example, global knockout of LAG-3 in non-obese diabetic 
(NOD) animals resulted in accelerated progression to T1D [155, 158]. 
 
1.6.3 LAG-3 cleavage and soluble LAG-3 
For optimal CD4+ T cell activation to ensue, LAG-3 must undergo proteolytic cleavage from the 
cell surface, thus allowing CD4’s activation signal to proceed.  The disintegrin/matrix 
metalloproteases ADAM10 and ADAM17 have been shown to mediate LAG-3 cleavage in its 
connecting peptide region [144, 159]. ADAM10 and ADAM17 have also been shown to mediate 
membrane shedding of TNFα [160], Notch [161, 162], CD62L (L-Selectin) [163, 164], and 
CD44 [165], to name a few.  Specifically, ADAM17 activity is redox-dependent, as it requires 
alterations by ROS to mediate conformational changes [166, 167].  Maintenance of LAG-3 on 
the surface of CD4+ T cells either by metalloprotease inhibition via chemical inhibitor [159] or 
redox modulation [168], or mutating the cleavage site within LAG-3 [144], resulted in dampened 
T cell proliferation and effector function. 
The resulting cleaved portion of LAG-3, or soluble LAG-3 (sLAG-3), can be detected in 
both human and murine serum during immune responses.  sLAG-3 has been shown to be a 
robust measure of T cell activation in vivo, as high serum levels correlated with positive 
prognosis and survival in progesterone or estrogen receptor positive breast cancer patients [169].  
In a study examining Th1 and Th2 responses in Mycobacterium tuberculosis patients, those who 
received antimycobacterial treatment and had better prognostic outcome, exhibited higher levels 
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of serum sLAG-3 as compared to untreated patients [170]. Previous work from our laboratory 
demonstrated that sLAG-3 may also serve as an early stage biomarker for Type I Diabetes (T1D) 
onset in animal studies [168], and work examining sLAG-3 levels in samples from T1D patients 
and first degree relatives have been promising (Delmastro-Greenwood et al.; unpublished work).   
 
1.6.4 LAG-3 as a marker of T cell exhaustion 
One of the main areas of research that has further elucidated the inhibitory role of LAG-3 is 
through the study of T cell exhaustion.  T cell exhaustion is a phenomenon that occurs in cancer 
and chronic viral infection, where due to the constant bombardment with antigen and persistent 
inflammation, T cell responses wane.  Not only do exhausted T cells demonstrate a unique 
transcriptional program, but overexpression of specific surface markers is one of the key 
determinants in exhaustion [171].   These surface markers include not only LAG-3, but also 
programmed cell death-1 (PD-1), cytotoxic T lymphocyte antigen-4 (CTLA-4), and T-cell 
immunoglobulin domain and mucin domain (TIM-3), to name a few [171, 172].  Expression of 
these receptors in various combinations has been observed, depending on the disease.  For 
example, in models of murine B16 melanoma, MC38 colon adenocarcinoma, and Sa1N 
fibrosarcoma, dual expression of LAG-3 and PD-1 was observed on exhausted CD8+ and CD4+ 
tumor-infiltrating lymphocytes (TIL) [173]. LAG-3 has also been observed on exhausted CD8+ T 
cells in a murine model of lymphocytic choriomeningitis virus (LCMV) [156] and in human HIV 
patients [174].  While exhaustion has been studied predominantly in CD8+ T cells, there is 
evidence of CD4+ T cells experiencing a similar fate.  In models of Plasmodium malaria [175] 
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and B16 melanoma [176] dual expression of LAG-3 and PD-1 identified hyporesponsive CD4+ T 
cells, and targeting both molecules via antibody blockade restored CD4+ T cell responses.  
 
1.6.5 Regulatory T cell function via LAG-3-mediated inhibition 
As activated T cells have been shown to be high expressers of LAG-3, so have some CD4+ 
CD25+ Foxp3+ T regulatory (Treg) cells.  Naturally occurring Tregs make up 5-10% of the human 
CD4+ T cell repertoire and are required for maintaining immune homeostasis, protecting against 
autoimmunity, and controlling chronic inflammation [177].  Tregs utilize several mechanisms for 
suppressing immune responses, including secretion of inhibitory cytokines like IL-10 and TGFβ, 
sequestration of IL-2 and adenosine, two necessary factors for optimal T cell activation, and 
direct cytolysis of Teff by granzyme B/perforin release [177].  Increased frequencies of Tregs have 
been demonstrated in several solid tumor models and correlate with negative prognostic 
outcomes [178, 179].  Alternatively, defects in Treg populations correlate with increased 
autoimmune disease [180, 181]. 
Subsets of Tregs in both murine and human studies have been shown to express LAG-3 on 
their surface, supporting LAG-3 as a marker for these cells [182, 183].  Also, LAG-3 has been 
implicated as a mechanism utilized by Tregs to mediate immunosuppression, either by targeting 
dendritic cells (DCs) or Teff directly.  LAG-3+ Tregs can engage immature DCs via LAG-3 
binding to MHC class II on the DC, thereby suppressing DC maturation and altering DC 
differentiation toward a tolerogenic phenotype [184].  Studies by Camisaschi et al. identified a 
LAG-3+ CD4+ CD25hi Foxp3+ Treg population in both healthy donors and melanoma and 
colorectal cancer patients [140].  The frequency of this Treg population was increased in the 
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peripheral blood, lymph nodes, and tumor microenvironment of the cancer patients.  These LAG-
3+ Tregs produced higher levels of IL-10 and TGFβ, as compared to LAG-3- Tregs, and their 
suppressive capacity was dependent upon cell-to-cell contact.  Additionally, in an in vitro 
suppression assay, LAG-3+ Tregs induced greater Teff suppression as compared to LAG-3-
deficient Tregs, further implicating LAG-3 as a marker for potent Tregs [140]. 
 
1.7 AUTOIMMUNITY AND IMMUNOMETABOLISM 
1.7.1 Immunometabolism and insight into autoreactivity 
As with T1D and other autoimmune diseases, there is still a gap in our understanding regarding 
autoreactive T cells.  However, understanding how cellular bioenergetics and biosynthesis shape 
both immune cell differentiation and function provide an avenue for expanding our knowledge 
regarding what is inherently different about autoreactive T cells, and how to exploit these 
differences to control autoimmunity.  Work reported thus far has revealed that metabolic 
differences do exist between autoreactive T cells and their non-autoreactive counterparts [185-
187].  For instance, studies from Yin et al. have shown that autoreactive T cells from patients 
with systemic lupus erythematosus (SLE) demonstrate enhanced aerobic glycolysis and 
OXPHOS during activation, enabling increased IFNγ production [188].  By targeting these 
pathways with the chemicals 2-DG and metformin, respectively, T cell bioenergetics were reset 
to the levels of T cells from healthy controls.  This metabolic-based treatment also normalized T 
cell metabolic dysfunction in animal models of SLE, resulting in significant reductions in disease 
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pathology [188].  Nevertheless, treatment cessation led to flare ups in animals, suggesting that 
while metabolism-targeted treatment ameliorated disease, it did not generate durable tolerance 
[189]. 
 Patients with multiple sclerosis (MS) exhibit increased concentrations of glutamine and 
glutamate in their cerebrospinal fluid and brain biopsies[190, 191].  As increases in glutamine 
and glutamate are associated with disease severity, concentrations of these metabolites have been 
suggested as potential biomarkers for MS [190, 191].  Earlier, it was discussed that glutamine 
metabolism via glutaminolysis is crucial for CD4+ T cell differentiation and cytokine production 
(see section 1.3.2).  Studies in experimental autoimmune encephalomyelitis (EAE), the murine 
model of MS, have shown that knockout of the glutamine transporter ASCT2 resulted in reduced 
Th17 cytokine production, diminished lymphocyte infiltration into the central nervous system, 
and lessened disease severity [111].  Together, these results suggest that glutamine is a critical 
metabolite for pathogenic T cells in MS, and targeting this pathway in patients could be 
efficacious.   
 As described earlier, mitochondria are at the center of metabolic function in T cells, and 
mitochondrial dysfunction is known to contribute to autoreactivity [185-187].  SLE T cells 
demonstrate elevated mitochondrial membrane potential and increased ROS production [192, 
193].  This is in part due to an increased reliance on glucose oxidation, which occurs in the 
mitochondria, rather than aerobic glycolysis [189].  In Rheumatoid Arthritis (RA), hypoxia and 
increased pro-inflammatory cytokine production in synovial joints are associated with increased 
mitochondrial DNA mutations [194, 195].  Of note, hypoxia led to reduced expression of 
respiratory chain subunits, thereby contributing to mitochondrial dysfunction [195].  
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 Overall, autoreactive T cells do not play by the same metabolic rules as other T cells.  
These metabolic differences do contribute to pathogenicity, and metabolic-based therapies could 
be the next frontier in treatment for autoimmunity. 
 
1.7.2 Immunometabolism and T1D  
While work in other autoimmune diseases has furthered our understanding of 
immunometabolism, there remains a gap in knowledge concerning T cell metabolism in T1D.  
Studies in the NOD mouse have shown that T regulatory cells are present in the pancreas in the 
early stages of disease, and they can suppress early effector T cell responses [196].  However, 
there is a tipping point where effector T cells become refractory to Treg-mediated suppression.  
This is not simply a numbers game because at low Treg to effector T cell ratios, effector 
activation and function prevails, and it is not due to defects in the Tregs themselves as they can 
suppress non-diabetogenic T cells [196].  These studies beg the question of what is inherently 
different about these autoreactive T cells, and examining T cell bioenergetics could provide 
crucial insight.  The body of work presented here was developed to further explore the 
mechanisms that govern metabolic pathways in CD4+ T cells as a means of potentially 
controlling autoimmunity in T1D.      
LAG-3 has been shown to have a critical role in modulating autoreactive T cell responses 
in T1D.  Studies by Bettini et al. indicated that LAG-3-deficient NOD animals exhibited 
accelerated T1D progression compared to wildtype controls, and LAG-3 inhibition by antibody 
blockade yielded similar results [155].  Studies from our laboratory corroborated these findings 
by indicating that inhibition of LAG-3 cleavage from NOD T cells delayed T1D onset [168].  
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Moreover, in non-autoimmune strains, LAG-3 is a negative regulator of naïve T cell homeostatic 
expansion [157]. As described earlier, the ability for any cell to proliferate is controlled by 
nutrient availability, and converting those nutrients to energy and macromolecules.  Other 
inhibitory receptors have also shown to modulate T cell metabolism [197, 198].  Therefore, we 
hypothesized that LAG-3 regulates T cell responses by modulating their bioenergetic profile.     
Furthermore, previous reports from our laboratory and others demonstrated that 
inhibiting ROS production during T cell activation resulted in reduced effector function 
transition, clonal expansion, and T1D progression, in conjunction with maintenance of LAG-3 
surface expression [168, 199-202].  Additionally, ROS have been implicated as critical signaling 
molecules in mediating metabolic changes in other disease models [43, 185, 203, 204].  With 
this, and that IFNγ production and proliferation are dependent upon T cells transitioning to 
aerobic glycolysis, we hypothesized that ROS are critical for enabling metabolic reprogramming 
in T cells during T1D induction. 
  
1.8 REACTIVE OXYGEN SPECIES MEDIATE T1D IMMUNOPATHOLOGY 
Decades of research have demonstrated that T1D pathology and inflammation is highly mediated 
by ROS and oxidative stress [16, 205-207].  This includes ROS being necessary for activating 
both the innate and adaptive immune responses.  In particular, it has been reported that T cells 
require acute doses of ROS to facilitate proliferation and differentiation [208-210].  The doses of 
ROS present during T cell activation have a dramatic effect on the outcome of the immune 
response generated, as too little ROS results in antigen hyporesponsiveness, and high doses lead 
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to oxidative stress-induced apoptosis [211-213].  Therefore, controlling cellular redox is of 
utmost importance in controlling T cell responses.   
T1D progression, and autoimmunity in general, occurs when central and peripheral 
tolerance mechanisms break down.  Central tolerance refers to elimination of autoreactive T cells 
in the thymus during development; whereas, peripheral tolerance refers to mechanisms outside of 
the thymus, like suppression by regulatory T cells.  While the predominant focus has been on the 
influence of ROS during T cell activation, redox has also been shown to play a significant role 
during thymocyte development and in T regulatory cell formation and function.  Therefore, to 
fully understand the broad influence of cellular redox on T cell function in the context of T1D, a 
systematic approach must be conducted to fully dissect the direct and indirect effect these signals 
have on modulating T cell responses.    
Although the etiology of T1D is still not completely understood, it is well accepted that 
T1D is driven, in part, by oxidative stress [16, 205-207].  In fact, murine β cells are highly 
susceptible to oxidative stress since they demonstrate low antioxidant enzyme expression [214], 
yet generate high levels of mitochondrial-derived ROS via glucose oxidation  [215-217].  These 
ROS are necessary for activating both the innate and adaptive immune responses.  In the context 
of T1D, β cell ROS production and antigen release can activate islet-resident macrophages and 
dendritic cells (DCs) (Figure 4).  These innate cells, also known as antigen presenting cells 
(APC), phagocytose β cell antigens and ferry them to the pancreatic draining lymph nodes [16].  
In the draining lymph node, activated APCs present β cell antigens to self-reactive CD4+ and 
CD8+ T cells, in the context of co-stimulation, along with pro-inflammatory cytokines and ROS.  
Together, these signals result in T cell activation and trafficking to the pancreas. Both CD4+ and 
CD8+ T cells are present in pancreatic islet infiltrates during T1D progression [7, 8, 218].  T cells 
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induce β cell destruction by either direct killing (CD8+ T cells) or production of inflammatory 
cytokines like Interferon γ (IFNγ) and tumor necrosis factor α (TNFα) (CD4+ T cells) [16, 219].  
This induced killing results in more β cell antigen and ROS release, thereby activating more 
APCs and continually driving this vicious cycle.  With respect to CD4+ T cells, their importance 
in T1D pathogenesis was exemplified by studies demonstrating that CD4+ T cell depletion 
completely prevented disease progression [218, 220].  In particular, T cells have been shown to 
require acute doses of ROS to facilitate activation and effector function [208-210].  These ROS 
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Figure 4.  The role of ROS in driving the immunopathology of Type 1 Diabetes (T1D). 
Reactive oxygen species (ROS) have been shown to be critical mediators of β cell destruction in Type 1 Diabetes.  
Not only do β cells themselves produce high levels of ROS that can induce cell death, but these ROS can also prime 
activation of infiltrating antigen presenting cells (APCs) like macrophages.  APC-derived ROS can also contribute 
to β cell loss directly.  Once activated, APCs then traffic to the pancreatic lymph node, where ROS serve as third 
signal during T cell activation.  Activated T cells then traffic to the pancreas and drive β cell apoptosis via 
inflammatory cytokines, direct β cell lysis, and ROS production via NADPH oxidase expression.  
 
 
1.9 SOURCES OF ROS THAT INFLUENCE T CELL FUNCTION 
Once naïve T cells receive all three signals to become activated (antigen presentation, co-
stimulation, and cytokines/ROS), undergo two major processes -- clonal expansion and 
differentiation .  ROS are known to modulate both processes, and there are multiple sources, both 
intrinsic and extrinsic, of ROS that T cells can encounter.    
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1.9.1 NOX-derived ROS 
NADPH oxidases (NOX) are intermembrane enzymes, which are the primary source of 
respiratory burst across many cell types.  NOXs are multimeric enzymes that consist of different 
combinations of subunits, depending on the specific isoform expressed. Of all immune cells, 
expression of a functional NOX is most highly associated with innate immune cells, including 
macrophages, neutrophils, and eosinophils [221, 222].  These cells express a phagocyte NOX, or 
NOX-2 isoform, comprised of the subunits cytochrome b558 (complex formed by p22phox and 
gp91phox), p40phox, p47phox, and p67phox (encoded by the genes Cyba, Cybb, Ncf4, Ncf1, and Ncf2, 
respectively) [223].  Of the NOX-2 subunits, the cytochrome b558 complex is membrane bound, 
while a complex of the remaining subunits exists in the cytosol.  Upon activation via 
phosphorylation of p47phox, the cytosolic complex translocates to the membrane, enabling a fully 
functional enzyme. Cytochrome b558 is then able to facilitate electron transfer from NADPH to 
oxygen, forming superoxide.  The factors flavin and heme associate with NOX-2 to enable 
electron transfer as well [223, 224].  
Further studies in T cells have demonstrated that they too express a phagocyte-type NOX 
(Figure 5).  Specifically, mRNA studies comparing murine primary T cells and T cell lines to 
macrophages indicated similar expression levels of the NOX genes Cyba, Cybb, Ncf1, and Ncf2, 
[225], and TCR-mediated activation of purified T cells resulted in generation of both superoxide 
and hydrogen peroxide [213, 225].  Of note, these studies were completed using APC-
independent mechanisms of T cell stimulation, indicating that ROS generated by T cells 
themselves are sufficient for mediating activation [213].  Upon knockout of p47phox, generation 
of hydrogen peroxide by T cells was severely blunted; yet, superoxide production remained 
intact.  Further manipulation using the flavin-dependent inhibitor diphenylene iodonium (DPI), 
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yielded similar results [213], suggesting that T cells may express other NOX isoforms that are 
non-flavin dependent.  Indeed, later studies confirmed T cell expression of DUOX-1, a calcium-
dependent NOX isoform that functions independently of p47phox [226].  Studies from Kwon et al. 
further demonstrated that DUOX-1 expression in T cells was responsible for very early hydrogen 
peroxide generation upon TCR engagement [226].  Examination of NOXs and DUOXs in other 
cell types have shown that the magnitude of ROS generation greatly differs, with NOXs 
providing more robust ROS production.  Therefore, the signals propagated by NOX and DUOX 
may result in different phenotypic outcomes in T cells, and further dissection in disease states, 
like T1D, is necessary.  
As both macrophages and T cells express functional NOXs, animals on the NOD 
background have been generated to study the contribution of these ROS to T1D pathogenesis.  
Specifically, the NOD.Ncf1mlJ contain a point mutation in the Ncf1 gene encoding for the p47phox 
subunit of NOX-2; thus, quenching global NOX-2 function and ROS production [200, 202].  
These animals demonstrate delayed T1D incidence as compared to their wildtype counterparts, 
which was attributed to reduced activation of both macrophages and T cells [200, 202].  
However, some CD4+ T cell responses do develop, yet rather than being Th1 (i.e. IFNγ), like that 
elicited in T1D, they are skewed to a Th17 phenotype, characterized by secretion of the cytokine 
IL-17 [202].  Consistent with these changes, the animals develop experimental autoimmune 
encephalomyelitis (EAE), the animal model of multiple sclerosis (MS).  Together, these results 
suggest that NOX-derived ROS enable autoreactive T cell activation in T1D.  However, 
lowering the oxidative threshold via NOX-2 inhibition allows for the activation of other 
autoreactive T cell clones, further solidifying that genetic predisposition to autoimmunity is 
ultimately paramount.        
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1.9.2 Macrophages  
One of the most well-characterized sources of ROS encountered by T cells is the macrophage.  
Under homeostatic conditions, low levels of tissue-resident macrophages are present in the 
pancreas, and upon an environmental trigger can become activated by β cell-derived ROS 
(discussed below) and peptides [16, 207].  Macrophages represent the predominant infiltrate 
during the very early stages of insulitis in T1D, as their increased ROS and pro-inflammatory 
cytokine production mobilizes and activates more macrophages [8, 227].  As stated earlier, 
macrophages are known to express NOX, which transport electrons across membranes, resulting 
in superoxide formation [221, 223, 224].  As superoxide itself cannot freely move across cellular 
membranes, dismutation to hydrogen peroxide allows for a potent ROS that can diffuse across 
the T cell membrane.  During macrophage-mediated activation of T cells, a tight immunological 
synapse is formed.  ROS are known to be very proximal signaling molecules; therefore, the tight 
synapse formed between the macrophage and T cell creates a spatial arrangement that fosters 
ROS signaling between the two cells.  Concentrations of hydrogen peroxide ranging from 10-100 
uM produced by macrophages are capable of initiating signaling cascades, including the 
mitogen-activated protein kinase (MAPK) [213], PI3/Akt [228, 229], and NF-κB [230] pathways 
in T cells.  These ROS can also perpetuate downstream TCR signaling [231], and together, result 
in T cell-mediated pro-inflammatory cytokine production [232, 233].  
In T1D, macrophages are the early islet infiltrators, and their activation is required for 
generating T cell responses and ensuing disease [234-236].  Not only can these ROS signal to T 
cells during MHC:TCR engagement, but they also activate the MAPK and NF-κB pathways in 
macrophages [237].  Both MAPK and NF-κB activation result in increased production of pro-
inflammatory cytokines like TNFα and Interleukin-1beta (IL-1β), which shape the T cell 
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response in addition to ROS signaling [238, 239].  Studies using chemical NOX inhibitors or 
NOX-deficient macrophages have demonstrated that inhibition of ROS in the macrophage can 
alter CD4+ T cell activation, resulting in delayed T1D progression [200, 202, 240].  Yet, 
reconstituting ROS production by either the T cell or macrophage is sufficient for restoring 
optimal crosstalk and activation, indicating that the source of ROS is not as crucial as the 
presence of ROS.      
 
1.9.3 Mitochondrial-derived ROS 
Mitochondria are also cellular sources of ROS, including in T cells.  Mitochondria are necessary 
for generating ATP via oxidative phosphorylation to power cellular processes.  Substrates such 
as glucose, fatty acids, and glutamine, can be oxidized via the Tricarboxylic acid (TCA) cycle 
and electron transport chain (ETC) in the mitochondria [35, 39].  The ETC consists of five 
mitochondrial complexes (I-V) which are important for coupling the transport of electrons with 
the transport of protons from the mitochondrial matrix into the intermembrane space [35, 39].  
NADH dehydrogenase (Complex I), succinate dehydrogenase (Complex II), and cytochrome c 
reductase (Complex III) are all capable of generating superoxide due to electron leak [38, 44].  
Superoxide produced by Complexes I and III is released into the mitochondrial matrix, where 
superoxide dismutase-2 (MnSOD) converts it to hydrogen peroxide [43].  Superoxide formation 
by complex III is released into both the mitochondrial matrix and intermembrane space and has 
been shown to be a potent signaling intermediate [241, 242].  Mitochondria have also been 
shown to migrate towards the immunological synapse (the TCR:MHC junction) within the T cell 
during activation.  This migration is dependent upon TCR-mediated calcium signaling and 
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results in increased mROS production [243].  While it has been shown that mitochondrial 
migration is important for maintaining calcium signaling during activation, it remains to be 
understood what role this juxtaposition plays for mROS signaling on T cell activation.   
During T cell activation, mitochondrial oxidation increases dramatically within the first 
24 hours of TCR engagement [244].  This increase, driven by calcium and adenosine 
monophosphate-activated protein kinase (AMPK) signaling, is necessary for cellular growth in 
preparation for cell division [102].  With increased oxidation, increased mitochondrial-derived 
ROS (mROS) also increases.  Work by Sena et al. demonstrated that mitochondria-derived ROS 
are essential for mediating the transition from naïve to effector in CD4+ T cells [244].  
Specifically, Complex III-deficient T cells demonstrated reduced activation marker expression 
(CD69 and CD25) and growth factor production (IL-2), in comparison to wildtype T cells [244].  
In vivo experiments utilizing T cell-specific Complex III knockout animals demonstrated similar 
results in both CD4+ and CD8+ T cells.  However, results from Tse et al. indicated that 
compensatory superoxide production from the APC should be sufficient for facilitating T cell 
activation in the instance that the T cell itself is deficient [202].  These conflicting results 
highlight that further delineation of superoxide production and signaling is necessary, and there 
may be strain-specific differences as Tse et al. utilized the NOD model whereas Sena et al. used 
C57Bl/6 animals.  Additionally, the source of ROS in these instances, the APC versus the T 
cell’s mitochondria, could mediate differential signaling. 
Mitochondrial dysfunction has been characterized in T cells from other autoimmune 
diseases [185-187]; however, similar studies remain to be performed using T1D-specific T cells.  
For example, T cells from Systemic Lupus Erythematosus (SLE) patients demonstrate elevated 
mitochondrial membrane potential and increased ROS production [192, 193].  This is in part due 
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to increased reliance on glucose oxidation, which occurs in the mitochondria, rather than aerobic 
glycolysis (which occurs in the cytosol), during activation [189].  Moreover, in rheumatoid 
arthritis (RA), hypoxia and increased pro-inflammatory cytokine production in synovial joints 
are associated with increased mitochondrial DNA mutations [194, 195].  Of note, hypoxia led to 
reduced expression of respiratory chain subunits, thereby contributing to mitochondrial 
dysfunction [195].  These studies set a precedence for mitochondrial dysfunction in enabling 
autoreactive T cells, and studies in T1D could provide further insight into inherent differences 
between autoreactive and non-pathogenic T cells.   
 
1.9.4 β cells 
Pancreatic β cells are responsible for dynamic glucose sensing and insulin secretion to maintain 
blood glucose homeostasis.  Acute doses of ROS are required for supporting insulin secretion 
[215-217]; therefore, β cells have mechanisms in place to provide the necessary oxidative 
signals.  First, β cells, like macrophages and T cells, express multiple NOX isoforms (NOX 1, 2, 
4, NOXA1, and NOXO1) [245-248].  Moreover, β cells demonstrate high levels of glucose 
oxidation in the mitochondria, thus resulting in increased mitochondrial-derived ROS [249-251].  
Interestingly, murine β cells demonstrate low antioxidant enzyme expression, making it difficult 
to maintain redox balance [214].  
 In T1D, β cell-derived ROS, coupled with antigen release, are responsible for activating 
and mobilizing APCs [16].  A positive feedback loop exists in that pro-inflammatory cytokine 
and ROS release by tissue resident APCs can induce more β cell ROS production.  T cell 
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activation in T1D occurs in the pancreatic draining lymph node; therefore, β cell derived ROS 
would not have a direct impact on this process.  However, an indirect effect does exist as APC 
activation is dependent upon β cell interactions, and how the APC is activated can then influence 
T cell mobilization.  Activated T cells that traffic to the pancreas can encounter β cell generated 
ROS, which can promote increased T cell NF-κB activation and pro-inflammatory cytokine 




Figure 5.  T cell intrinsic and extrinsic sources of ROS. 
A.  T cells express functional NADPH oxidases (NOX), which can generate ROS.  Additionally, oxidative 
phosphorylation in the mitochondria can result in ROS leak.  B.  During T cell – APC interaction, activated APCs, 
like macrophages, generate NOX-derived ROS that coupled with inflammatory cytokines, enable optimal T cell 
activation. 
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1.10 ROS AND THYMOCYTE DEVELOPMENT 
T cell development is an intricate process whereby thymocyte precursors move through various 
stages of differentiation in the thymus.  All early thymocytes start as CD4-CD8- double negative 
precursors [252].  The double negative stage is where TCR-β receptor rearrangement occurs and 
cells express a pre-TCR comprised of a β chain and a pre-Tα chain.  From there, double negative 
cells differentiate to double positive (DP) CD4+CD8+ thymoctyes.  At this time, TCR α chain 
rearrangement occurs and a mature αβ TCR is expressed.  DP thymocytes then undergo two 
critical developmental processes – repertoire selection and lineage commitment.  T cell 
repertoire selection includes both positive and negative selection where thymocytes interact with 
MHC loaded with self-peptides [252-254].  Low affinity for self-peptide/MHC results in 
maturation to a single positive T lymphocyte.  Interestingly, 90% of thymocytes die by neglect at 
this stage, as their TCR is inert [253].  Alternatively, high affinity for self-peptide/MHC results 
in apoptosis as a way of protecting against potentially autoreactive T cells escaping into the 
periphery [253, 254].  This is known as central tolerance.  It is here, during negative selection, 
that disease progression initiates in autoimmune-prone individuals, although the mechanisms by 
which self-reactive T cells escape deletion are not fully understood.    Lineage commitment, or 
commitment to either a CD8+ or CD4+ single positive T cell occurs based on successful 
engagement of either MHC class I or II, respectively.  Once matured, T lymphocytes then exit 
the thymus and begin to seed the periphery.   
Cellular redox is critical for thymocyte development and selection.  Specifically, 
thymocytes express a family of proteins, known as the uncoupling proteins (UCP) 1-3 [255-258].  
This group of proteins reside in the mitochondria and serve as proton transporters, thereby 
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dissipating the proton gradient created in the mitochondrial matrix.  Thus, oxidative 
phosphorylation is uncoupled from ATP production, and uncoupling can lead to increased 
electron leak and ROS production.  Several groups have shown that expression levels of UCP 1-
3 in the thymus fluctuate with age, and murine studies using individual UCP knockouts have 
shown alterations in percentages of double and single positive populations [259, 260], further 
indicating their requirement at different stages of thymocyte development.  Loss of UCP-1 
expression specifically, results in increased mitochondrial oxygen consumption, ROS and ATP 
production, and lowered apoptotic potential [259, 261].   
Another way in which redox regulates thymocyte development is through the control of 
the redox-sensitive transcription factor NF-κB, as activation in the cytoplasm can be initiated by 
ROS.  This upstream activation can result in phosphorylation of either IκB or IκBα, allowing for 
release of p50/p65 and its translocation to the nucleus [262, 263].  Alternatively, in the nucleus, 
reduction of the cysteine 62 residue of the p50 subunit is required for optimal DNA binding 
[264].  Antioxidant treatment [265] and Cu/Zn SOD overexpression [266] have both been shown 
to result in dysfunctional thymocyte development, due to defective NF-κB signaling.  This is 
explained by the fact that NF-κB can also serve as a survival signal, and as demonstrated in 
developing T lymphocytes [267].  These studies underscore that there is a fine balance between 
ROS generation and antioxidant capacity, and alterations could set the stage for the formation of 
autoreactive T cells and autoimmunity.   
It has been well-established that breakdowns in central tolerance in the thymus do occur 
and lead to T1D progression [268].  Some studies have demonstrated that reduced insulin 
transcript levels in the thymus correlated with increased susceptibility to T1D [269, 270]; 
thereby, providing direct evidence that alterations in thymic selection influences autoimmune 
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progression.  Further studies in the NOD model have indicated that self-reactive T cells and 
thymocytes are genetically programmed to be more resistant to apoptosis [271-273], exemplified 
by studies showing NOD thymocytes were more resistant to apoptosis induced by 
dexamethasone (Dex) treatment [274, 275].  Thymocytes protected from Dex-induced apoptosis 
demonstrated increased SOD expression, indicating that increased antioxidant enzyme 
expression is beneficial in this context [276].  The NOD mouse has also been shown to 
demonstrate increased NF-kB signaling in various cell types in comparison to non-autoimmune 
strains [277, 278].  While this has not been shown specifically in thymocytes, we would 
postulate that thymocytes from these animals demonstrate a similar phenotype.  This increase 
could also contribute to thymocyte resistance to apoptosis, reduced negative selection, and 
increased pro-inflammatory cytokine production in the periphery, contributing to disease 
progression.   
1.11 REDOX REGULATION OF T CELL ACTIVATION 
Balancing cellular redox has a critical impact on T cell activation and longevity.  Acute doses of 
ROS, either generated by the T cell itself or from an extrinsic source (i.e., macrophages) are 
necessary for driving the transition from naïve to effector (Figure 6) [213, 226, 244, 279].  
However, like other cell types, suboptimal or excessive concentrations of ROS can result in 
hyporesponsiveness [168, 199, 200] or oxidative stress, respectively, which can have profound 
implications on T cell functionality and immunity.  Studies have shown that resistance to 
oxidative stress increases with differentiation from naïve to effector [209, 280, 281].  This is 
likely due to effector T cells traveling to highly inflamed and hypoxic tissues; whereas naïve T 
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cells remain in the normoxic lymph nodes and lymphatics.  Therefore, the influence of ROS on T 








Figure 6.  The influence of ROS on T cell outcome during activation. 
The dose of ROS present during T cell priming and activation can have a dramatic effect on effector T cell outcome.  
High levels of ROS can induce oxidative stress and DNA damage, resulting in T cell death, while low levels will be 
inefficient at driving optimal activation.  Moderate levels, either produced by APCs or T cells themselves, ensure 
proper TCR signaling, clonal expansion, and effector differentiation.  
 
  
1.11.1 Redox modulation of TCR signaling 
Downstream signaling initiated by the TCR upon MHC-peptide recognition is essential for 
antigen-specific T cell activation.  This signaling is propagated by numerous adaptor proteins, 
kinases, and calcium signaling [282].  In addition, protein tyrosine phosphatase (PTP) inhibition 
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aids in signal maintenance [283].  With respect to TCR signaling, several adaptor proteins and 
downstream signaling cascades have been shown to be redox sensitive (Figure 7).  For instance, 
lymphocyte-specific protein tyrosine kinase (Lck), a member of the Src family of kinases,  which 
interacts with the cytoplasmic tail of both CD4 and CD8, is required for potentiating intracellular 
TCR signaling [280, 284].  Low doses of hydrogen peroxide are capable of inducing Lck 
phosphorylation (Try394), resulting in increased catalytic activity [285, 286].  Activation of Lck 
results in phosphorylation of both the CD3 ζ chains and another kinase Zap70.  Micromolar 
concentrations of hydrogen peroxide also stimulate Zap70 activation [287].  Furthermore, 
increased protein kinase C (PKC) and MAPK signaling and intracellular calcium levels have all 
been shown to be stimulated by hydrogen peroxide [288, 289].  
LAT, or linker for activation of T cells, is an adaptor protein associated with the TCR 
[282].  With TCR engagement, LAT serves as an anchor for formation of multiprotein signaling 
complexes, aiding in amplifying TCR signaling.  Work by Gringhuis et al. demonstrated that 
LAT’s localization to the plasma membrane is highly redox sensitive.  Specifically, LAT 
contains a cysteine residue that upon oxidative modification, results in a conformational change 
that inhibits interaction with glycolipid-enriched microdomains of the plasma membrane [290].  
This modification increases during times of oxidative stress and results in reduced Interleukin-2 
(IL-2) production by T cells [291].  This specific modification was demonstrated by T cells 
isolated from RA patients, due to high levels of inflammation [291].  Like RA, T1D is also 
highly driven by ROS and inflammation, and inflamed islets demonstrate high levels of oxidative 
stress [16, 206, 292].  It is interesting that with this highly oxidative environment, T cell 
responses are still occur, resulting in T1D progression.  These results highlight that while both 
RA T cells and T1D T cells share autoreactivity, their resistance to oxidative stress may greatly 
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differ. Side-by-side comparison studies may help elucidate potential differences.  A reducing 
environment between the APC and T cell is also critical for facilitating TCR signaling as T cells 
increase reduced thiols at the plasma membrane [293], and APCs support this milieu by secreting 
cysteine into immunologic synapse [294].  Together, these studies exemplify that while ROS 















Figure 7.  TCR signaling is highly redox dependent.  
Many components downstream of the TCR have been shown to be redox dependent, and alterations in redox status 
can result in suboptimal or completely inhibited TCR signaling.  Calcium channel signaling that occurs during TCR 
stimulation has also been shown to be redox dependent.  Red stars indicate those proteins/channels that are known to 
be influenced by redox.  Protein tyrosine phosphatases (PTPs), Protein lipase C (PLC), Linker for activation of T 
cells (LAT). 
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1.11.2 Redox cycle within the cell cycle 
As naïve T cells are relatively quiescent, they primarily reside in G0 phase of the cell cycle [52, 
59].  ROS are potent cell cycle entry signals in T cells and other cell types alike [295].  To enter 
the cell cycle during activation an oxidative event, like hydrogen peroxide or superoxide 
signaling, must occur [296, 297].  Additionally, ROS are required for S phase entry and DNA 
replication, as without ROS, cells arrest at the G1/S checkpoint [298].    
Mitochondrial metabolism, a major producer of ROS, increases in the early stages prior 
to cell cycle entry potentially ensuring that the signals for progression are present, and enabling 
necessary cell growth prior to division [43].  Mitochondrial ROS can activate the protein Romo1, 
which in turn impairs the cell cycle inhibitor p27 Kip1, allowing proliferation to progress [299]. 
This increase occurs simultaneously with reduced manganese superoxide dismutase (MnSOD) 
expression during the later stages of the cell cycle (S, G2, and M), to allow for oxidative signals 
to prevail [43].  
With balancing ROS to drive proliferation, the antioxidant glutathione is also balanced 
within the cell.  The positioning of glutathione is a direct indicator of cell cycle phase in that a 
more cytoplasmic location is indicative of G0/G1 phase [300-302].  Movement of glutathione into 
the nucleus is indicative of S phase and mitosis initiation [300].  T cell proliferation is also 
highly dependent upon glutathione in that treatment with a gamma-glutamylcysteine synthase 
inhibitor, L-buthionine-(S,R)-sulfoximine (BSO), inhibited DNA synthesis and thus T cell clonal 
expansion [303].  
Work by our laboratory and others have suggested the beneficial effects of a manganese 
metalloporphyrin as a means of modulating immune responses in T1D, due to its highly 
oxidative nature [199, 201, 292]  These studies have demonstrated that modulating the redox 
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balance of T cells results in reduced proliferation and cell cycle progression [168, 304].  As T 
cell effector function (IFNγ production) is tightly coupled to proliferation [305], inhibition of 
ROS also resulted in reduced cytokine production. 
1.12 ROS AND T REGULATORY CELLS 
As their name suggests, the role of T regulatory cells (Tregs) is to temper active immune 
responses and protect against unwanted responses, like those demonstrated in autoimmunity.  
Tregs are capable of inhibiting both innate and adaptive responses by modulating APCs or T cells 
through numerous mechanisms, including:  immunosuppressive cytokine secretion (i.e. TGFβ 
and IL-10), inhibitory receptor engagement (i.e. PD-L1 and CTLA-4), and amino acid 
scavenging (i.e. tryptophan and cysteine) [177, 306].  The importance of Tregs in suppressing 
autoimmune responses was highlighted by studies demonstrating that reconstitution of athymic 
mice with Teff resulted in systemic autoimmunity [307].  This ensuing autoimmunity was only 
suppressed upon adoptive transfer of CD4+CD25+ T regulatory cells [307].  While Tregs have 
been shown to be derived from both CD4+ and CD8+ T cell lineages, the most well-studied are 
the naturally occurring CD4+ Tregs that demonstrate surface expression of the high affinity IL-2 
receptor, CD25 [306, 308].  Other surface markers have been used to delineate different subsets 
of Tregs including, CTLA-4, LAG-3, and PD-L1 [177] Most importantly of all Treg markers, 
expression of the transcription factor Forkhead box P3 (FoxP3), is essential for driving necessary 
genes for Treg function and development [309]. 
As in Teff, expression of a functional NOX in Tregs has been shown to have a dramatic 
effect on their development and suppressive capabilities.  In models of inducible Tregs, studies 
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demonstrated that macrophage-derived ROS via NOX were necessary for supporting optimal Treg 
differentiation [310].  In vitro co-cultures of naturally occurring Tregs and Teff indicated that Tregs 
deficient in NOX (Ncf-1-/-) were less capable of suppressing Teff proliferation via TGF-β 
production, as compared to WT Tregs [311].  TGF-β production in other cell types has been 
shown to be redox sensitive, as antioxidant treatment with N-acetylcysteine (NAC) resulted in 
reduced expression of the cytokine [312].  Additionally, TGF-β can induce NOX expression and 
activity [313, 314].  Taken together, these studies highlight the necessity for Tregs to produce 
ROS to maintain suppressive functionality.  While suppression was measured by inhibition of 
Teff proliferation, the effector cytokine response was not examined.  As the presence and absence 
of ROS during Teff activation have been shown to skew towards distinct T helper subsets, 
characterization of the cytokine profile may have elucidated if NOX expression by Tregs 
influences this as well.  Also of note, not all Tregs mediate suppression via TGF-β; therefore, the 
requirement for NOX may differ, depending upon the mode of suppression.            
Tregs demonstrate an enhanced ability to circumvent oxidative environments.  Polarization 
of CD4+ T cells to Tregs under hypoxic conditions increased Treg yields in vitro [315].  Not only 
were more Tregs generated, but they also demonstrated enhanced FoxP3 expression as compared 
to those cultured under normoxic conditions.  Although, the enhanced FoxP3 expression had no 
apparent effect on suppressive capacity [315].  Tregs also demonstrate high levels of cell surface 
thiols, which aid in counteracting oxidative stress [316].  Studies using human Tregs have shown 
they possess increased expression of the antioxidant enzyme thioredoxin, compared to 
conventional T cells, also enabling improved ROS scavenging [317].  These reducing 
mechanisms protect Tregs from oxidative stress-induced cell death, while maintaining their 
immunosuppressive function [316, 317]. 
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Based on these studies, presumably Tregs would be better equipped to thrive in the highly 
oxidative environment of the pancreatic islet, resulting in greater immune regulation.  Tregs are 
present in the pancreas preceding diabetes onset; however, they are accompanied by activated 
effector T cells as well [318].  Adoptive transfer studies of Teff with Tregs from non-diabetic NOD 
donors revealed a significant delay in T1D progression as compared to transfer of these subtypes 
isolated from diabetic animals [196].  Interestingly, Tregs from diabetic animals successfully 
suppressed effectors from non-diabetic donors, indicating that Treg functionality is maintained 
during overt disease.  However, Tregs from non-diabetic donors were unable to suppress Teff from 
diabetic donors in vivo [196]. This underscores that while Treg functionality may be intact in 
T1D, Teff surpass a pathogenic threshold that enables them to escape suppression.  
In work by Padgett et al., NOD.BDC.2.5.Ncf-1m1J mice were generated to study the 
influence of NOX-derived ROS on an antigen-specific model of T1D.  Results demonstrated that 
these NOX-deficient CD4+ T cells were more reactive to antigen as compared to their wildtype 
counterparts [319], and adoptive transfer experiments further elucidated that this enhanced 
diabetogenicity was due to defective regulatory T cell suppression.  While there have been 
human studies that also showed defective regulatory T cell responses in T1D patients and at-risk 
relatives [320-322], there is a lack of evidence linking this to redox-related mechanisms or 
specifically, NOX machinery.  Alternatively, effector T cells from T1D patients have also shown 
enhanced resistance to Treg-mediated suppression [323].  Therefore, aiming to amplify Treg 
suppressive capacity may prove ineffective.  A more suitable approach could be to make Teff 
more vulnerable to mechanisms of Treg suppression; thereby, allowing the immune system to 
remedy the situation itself. 
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1.13 ROS AS A THERAPEUTIC TARGET IN T1D 
As mentioned previously, the NOD mouse model is used to recapitulate T1D as these mice 
develop spontaneous autoimmune diabetes.  In addition, the adoptive transfer of BDC-2.5.TCR 
transgenic splenocytes into NOD.scid mice leads to rapid immune-mediated β cell destruction 
and diabetes onset within 7-14 days.  To understand the role that ROS play in the NOD 
spontaneous T1D model, the NOD.NCF-1mlJ model was developed [202].  These mice contain a 
point mutation that results in truncation of the p47phox subunit and prevents functional NOX 
assembly and ROS production [200, 202].  NOD.NCF-1mlJ mice experienced a delay in 
spontaneous diabetes progression, in large part due to suboptimal immune activation [200, 202, 
240].  These results further supported targeting NOX and ROS as a potential therapeutic in T1D. 
To combat the chronic inflammation and oxidative stress displayed in diabetes, 
manganese metalloporphyrin antioxidants (MnTE-2-PyP5+, MnP) are seemingly a viable 
therapeutic.  Not only can these agents scavenge free radicals, but they also possess a high 
bioavailability and are catalytic, displaying oxidoreductase properties [292, 324].  These 
characteristics allow for preservation of β cell integrity [325-327] and dampening of anti-islet 
immune responses in T1D [168, 199, 201]. 
 
1.13.1 MnP treatment delays Type 1 Diabetes onset in murine models 
Early studies investigating redox modulation via MnP treatment in T1D were performed using an 
adoptive transfer model of the diabetogenic BDC2.5 T cell clone into NOD.scid animals [199].  
MnP intraperitoneal injections were continued several days during the experiment, and then 
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ceased.  Of the mice treated with MnP, 50% developed diabetes by 28 days post-transfer, while 
100% of the untreated animals progressed to fulminant disease [199].  Most notably, histology 
results showed decreased pancreatic immune cell infiltrate with MnP treatment.  Additional in 
vitro studies indicated that MnP treatment reduced IFNγ production by BDC-2.5 T cells, and 
inhibited respiratory burst of peritoneal macrophages upon LPS stimulation [199].  Together 
these results demonstrated the immunomodulatory capacity of MnP treatment in T1D and its 
potential therapeutic use in autoimmunity. 
More recent studies in T1D with MnP have included the use of 14-day sustain release 
MnP pellets implanted subcutaneously at the nape of the neck in NOD mice [168].  This 
administration allows for systemic MnP treatment, and drastically decreases the number of 
administrations.  In this study, all untreated NOD mice developed T1D by 20 weeks of age 
[168].  By 30 weeks of age, only 50% of animals treated with MnP developed diabetes.  These 
data, together with the data from the adoptive transfer models, further support targeting ROS for 
preventing T1D.  Nevertheless, the protective effects of MnP cease when treatment ends, as 25% 
more animals progressed to diabetes following MnP treatment conclusion [168].  Overall, MnP 
treatment does delay diabetes onset; yet, it does not provide durable tolerance.  Therefore, the 
need for other therapies in conjunction with MnP treatment is apparent. 
 
1.13.2 Manganese Metalloporphyrins and T cell inhibition 
As both CD8+ and CD4+ T cells play important roles in mediating T1D, our laboratory has 
performed extensive in vitro and in vivo work, including various T1D and transplantation 
models, in order to understand how MnP treatment modulates responses by both T cell subsets 
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[168, 199, 304, 328].  Each of these models serves as a potential mimic for delaying T1D onset 
and preserving transplanted allogenic β cell grafts in human T1D patients.  Specifically in CD8+ 
T cells, Sklavos et al. showed that proliferation and IFN-γ and TNF-α production were 
significantly inhibited by MnP treatment in a mixed lymphocyte reaction (MLR) [304].  
Cytotoxicity of MnP-treated and untreated CD8+ T cells was tested in an antigen-specific 
cytotoxicity assay, where MnP treatment resulted in a 50% reduction in targeted killing by CTLs 
[304].  MnP treated OT-I CD8+ T cells during in vitro stimulation with SIINFEKL peptide also 
exhibited similar reductions in IFN-γ and TNF-α production, proliferation, and targeted killing.  
In both models, the reduced cytotoxicity by MnP treatment was in part due to reduced expression 
of both perforin and granzyme B [304].  Taken together, the results from both the MLR and OT-I 
models indicated that MnP’s ability to inhibit CD8+ T cell activation and effector function was 
not specific to any one model, supporting its applicability to suppress diabetogenic and anti-graft 
T cell responses.  Here, MnP’s effects are relevant to islet transplantation in autoimmune prone 
individuals, as it would suppress both anti-graft and autoimmune responses. 
Delmastro et al. investigated the effects of MnP on activation and effector function of 
CD4+ diabetogenic T cells.  These studies used the NOD.BDC-2.5.TCR.Tg mouse expressing 
the rearranged TCR of the diabetogenic BDC-2.5 T cell clone that respond to the β cell antigen, 
chromogranin [329].  Splenocytes isolated from these mice were stimulated in vitro with their 
cognate peptide, mimotope, with or without MnP treatment.  In vitro results indicated that MnP 
treatment inhibited CD4+ T cell activation and effector function by reducing IFNγ production, 
proliferation, and CD69 (marker of activation) and Tbet expression [168].  These results 
correlated with MnP treatment inhibiting the cleavage of LAG-3.  As described previously, in 
order for optimal T cell activation, LAG-3 must be cleaved from the T cell surface by the 
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metalloproteases ADAM10 and ADAM17 [159].  ADAM17, like many metalloproteases, is a 
redox-dependent enzyme in that oxidation of specific cysteine residues must occur to change its 
confirmation from its latent to its activated form [330-332].  As MnP has been shown to 
scavenge ROS during immune cell activation, Delmastro et al. determined that MnP treatment 
inhibited ADAM17 activation, thereby maintaining LAG-3 expression on the T cell surface, 
leading to CD4+ T cell inhibition and delayed T1D onset [168]. 
In vivo studies by Delmastro et al. further showed that MnP treatment of diabetogenic 
splenocytes diminished their potential for inducing T1D in a murine adoptive transfer model.  
Severe combined immunodeficiency mice on the NOD background (NOD.scid), lacking 
endogenous adaptive immunity, received diabetogenic BDC-2.5.TCR.Tg splenocytes.  
Throughout the course of the study, serum was taken from the MnP treated and control animals, 
to measure levels of sLAG-3.  Results indicated that elevated levels of sLAG-3 (suggesting 
CD4+ T cell activation) correlated with progression to diabetes in untreated animals [168].  
Alternatively, sLAG-3 levels in MnP treated mice remained steady and all animals were 
euglycemic.  Collectively, these results not only demonstrate that MnP treatment in vivo inhibits 
T1D onset, but also that sLAG-3 may serve as an early biomarker of T1D progression. 
Recent work from our laboratory has demonstrated that MnP treatment can modulate the 
metabolic profile of diabetogenic T cells in vivo [328].  During in vivo studies, NOD.BDC-
2.5.TCR.Tg mice were either treated with or without MnP for 7 days, and then various metabolic 
pathways of bulk splenocytes were assessed.  Not only did MnP treatment inhibit diabetogenic 
potential of splenocytes in an adoptive transfer model, but it also resulted in reduced utilization 
of glucose via aerobic glycolysis [328].  While aerobic glycolysis was decreased, indicated by 
reduced lactate production, splenocytes demonstrated more efficient glucose oxidation.  These 
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effects were attributed to enhanced activation of the tricarboxylic acid cycle (TCA) enzyme, 
aconitase, which is responsible for catalyzing the reaction of citrate to isocitrate in the 
mitochondria.   
1.14 SUMMARY 
The goal of this body of work was to more fully elucidate mechanisms that govern the 
bioenergetics of CD4+ T cells, as a means of understanding potential therapeutic targets for 
ameliorating autoimmunity.  The focus on T cell metabolism was driven by the more recent 
insight that T cell differentiation and bioenergetics are greatly intertwined – T cell phenotype can 
dictate the metabolic pathways required for function and metabolism reinforces characteristics 
attributed to specific T cell subsets.  Moreover, studies in diseases like RA, SLE, and MS have 
indicated that autoreactive T cells are bioenergetically distinct from non-pathogenic T cells, 
suggesting these alterations contribute to disease.  Here, we utilized murine models of T cell 
homeostasis and T1D to elucidate how LAG-3 (Chapter 2) and ROS (Chapter 3) modulate T cell 
metabolism during these processes, respectively.     
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2.0  LYMPHOCYTE ACTIVATION GENE-3 MAINTAINS METABOLIC AND 
MITOCHONDRIAL QUIESCENCE IN NAÏVE CD4+ T CELLS 
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Lymphocyte Activation Gene-3 (LAG-3) is an inhibitory receptor expressed on the surface of 
various immune cells, including CD4+ T cells.  While LAG-3 is more frequently associated with 
exhausted effector and regulatory T cells, it is also a negative regulator of T cell homeostatic 
expansion.  Recent studies exploring how cellular metabolism dictates immune cell function and 
fate have elucidated that CD4+ T cell function is tightly coupled to bioenergetics. Therefore, 
given that LAG-3 is a regulator of CD4+ T cell homeostatic expansion, and the ability to 
proliferate is highly dependent upon metabolism, we hypothesized that LAG-3 regulates the 
metabolic profile of naïve CD4+ T cells.  Naive OT.II T cells were isolated from wildtype and 
LAG-3-/- animals, and analyzed by Seahorse Flux Analyzer. LAG-3-/- OT.II T cells demonstrated 
significantly increased basal respiration, spare respiratory capacity, and aerobic glycolysis, as 
compared to wildtype OT.II T cells, indicating an enhanced bioenergetic profile.  Further 
analysis indicated that LAG-3-deficient OT.II T cells displayed increased mitochondrial 
biogenesis, via increased signaling through the AMPK/Sirt-1 pathway.  In an adoptive transfer 
model of homeostatic expansion, LAG-3-/- OT.II cells expanded to a greater extent and continued 
to demonstrate an enhanced oxygen consumption and glycolysis as compared to WT OT.IIs.  
This proved to be extrinsically regulated, as LAG-3 blockade in WT recipients recapitulated 
similar results to LAG-3-/- T cells.  These results demonstrate that LAG-3 is critical for actively 
maintaining metabolic quiescence in naïve CD4+ T cells, and future directions include 
investigating this mechanism and its implications in autoimmunity.   
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2.2 INTRODUCTION 
CD4+ T cells are a critical component of the adaptive immune system, thereby regulating their 
development, activation, and survival is of the utmost importance.  Homeostasis is an essential 
period of the T cell lifespan, during which T cells require low-level TCR stimulation and gamma 
chain cytokines (i.e. IL-7 and IL-15) to ensure their survival [59, 333].  In immunocompetent 
environments, naïve T cells actively maintain quiescence as a means of avoiding over population 
and loss due to neglect [52].  Alternatively, in lymphopenic hosts, naïve T cells exhibit increased 
proliferative capacity as a means of reconstituting the host’s immune system.  At various times 
during homeostatic expansion, naïve T cells can adopt a more memory-like phenotype, including 
increased CD44 and CD25 expression and faster transition to effector function upon antigen 
encounter [99, 100, 334].  Regulatory mechanisms are in place to maintain naïve T cell 
homeostasis and quiescence to protect against aberrant T cell activation and hyperproliferation, 
like that demonstrated in autoimmunity and cancer. 
In particular, lymphocyte activation gene-3 (LAG-3; CD223) has gained prominence as a 
key inhibitory receptor in various disease models [168, 173, 335].  Structurally, LAG-3 and CD4 
are considered homologs, with the former demonstrating a higher affinity for their shared ligand, 
MHC class II [139, 146, 148].  While the various inhibitory effects mediated by LAG-3, 
including dampening proliferation and inhibiting IFNγ production [336, 337], have been 
characterized, its downstream signaling remains to be fully defined.  Naïve CD4+ T cells express 
low levels of LAG-3 in comparison to other T cell subsets [141]; nevertheless, LAG-3 
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engagement can still negatively regulate these cells.  Studies examining global knockout [157] 
and antibody blockade [338] indicated that homeostatic expansion is tightly regulated by LAG-3 
in immunocompetent and lymphopenic animals.  In addition, these studies suggested that LAG-3 
mediated this effect by tempering STAT5 signaling [338]. 
It is becoming more evident that cellular metabolic programs are essential for driving the 
identity and functionality of T cells during their various life stages.  Unlike activated T cells, 
which demonstrate robust aerobic glycolysis to maximize macromolecule synthesis and energy, 
naïve CD4+ T cells are considered metabolically quiescent [48, 49].  Naïve T cells rely 
predominantly on oxidative phosphorylation (OXPHOS) via the mitochondria for generating 
ATP [53, 339].  Signaling via the cytokine IL-7 in naïve T cells is essential for maintaining not 
only their survival via Bcl-2 expression, but also their bioenergetic profile [68, 91].  IL-7 has 
been shown to increase glucose uptake via increased glucose transporter expression, in an 
Akt/STAT5-dependent manner [68, 75, 91].  Alternatively, loss of CD127 (IL-7Rα) expression 
or antibody blockade disrupts naïve T cell homeostasis, resulting in decreased proliferation and 
viability [72, 340].      
Considering that loss of LAG-3 expression results in increased CD4+ T cell homeostatic 
expansion, and that the ability of a cell to proliferate is tightly coupled to its metabolic profile, 
we hypothesized that LAG-3 expression regulates naïve CD4+ T cell metabolism.  Our results 
indicate that indeed, LAG-3-deficient naïve T cells exhibited enhanced oxidative and glycolytic 
metabolisms, with this being attributed to increased mitochondrial content.  Also, this heightened 
bioenergetic profile allowed for greater homeostatic proliferation upon adoptive transfer.    
Moreover, LAG-3 antibody blockade of wildtype OT.IIs enhanced their metabolic capacity to 
levels similar to LAG-3 knockout T cells, suggesting that LAG-3 mediates regulation through 
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extrinsic signaling.  LAG-3-deficient T cells were also more resistant to IL-7 deprivation as 
compared to their wildtype counterparts, which was attributed to increased STAT5 activation 
concomitant with reduced expression of the inhibitory phosphatase PTEN.  Upon activation, 
LAG-3-/- T cells outperformed wildtype cells by demonstrating enhanced metabolic 
reprogramming and effector function.  These findings suggest that LAG-3 expression on naïve T 
cells acts as a metabolic regulator to protect against hyperproliferation and maintain naïve T cell 
homeostasis to ensure controlled T cell activation. 
2.3 MATERIALS AND METHODS 
2.3.1 Animals 
C57BL/6.Lag3-/- mice were bred and housed under pathogen-free conditions in the Animal 
Facility of Rangos Research Center, Children’s Hospital of Pittsburgh, University of Pittsburgh 
Medical Center (UPMC).  Female and male mice aged 8-12 weeks were used in all experiments.  
All animal experiments were approved by the Institutional Animal Care and Use Committee 
(IACUC) of Children’s Hospital.  C57BL/6 WT controls were purchased from Jackson 
Laboratories and housed with the Lag3-/- animals.  For Lag3-/-.OT-II transgenics, B6.Lag3-/- 
animals were crossed with B6.OT-II animals (JAX) to homozygosity for the Lag3 gene and 
heterozygosity for the OT-II transgene.  C57BL/6.Rag1-/- breeder pairs were a gift from the 
laboratory of Dr. Jay Kolls, MD, and animals were maintained in immunocompromised housing. 
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2.3.2 CD4+ T cell isolation 
Whole spleens from B6.Lag3-/-, B6.WT, WT.OT-II and Lag3-/-.OT-II animals were homogenized 
and red blood cells were lysed using RBC lysis buffer (Sigma).  CD4+ T cells were isolated by 
negative selection from splenocytes using EasySep Mouse CD4+ T cell Isolation kits (StemCell 
Technologies).  Purity was determined by flow cytometry. 
 
2.3.3 Metabolic Seahorse Flux Analyzer assays 
T cells were plated in Cell-Tak (Corning) coated Seahorse culture plates (Agilent) at 1 x 105 or 3 
x 105 per well in assay medium (unbuffered DMEM, 1% BSA, 1 mM pyruvate, 25 mM glucose, 
2 mM glutamine), and analyzed using the Seahorse XFe96 instrument (Agilent).  For 
mitochondrial stress tests, basal oxygen consumption (OCR) and extracellular acidification rates 
(ECAR) were measured for 30 minutes, and then cells were stimulated with oligomycin (Oligo; 
2 mM), Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP; 0.5 µM), 2-
deoxyglucose (2-DG; 100 mM) and rotenone/antimycin A (Rot/AntA; 100 µM each) (all 
inhibitors from Sigma).  Spare respiratory capacity (SRC) was determined by the difference 
between maximal OCR (following FCCP addition) and basal OCR.   
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2.3.4 Mitochondrial to nuclear DNA PCR 
DNA was isolated from 5.0 x 106 isolated CD4+ T cells from indicated animal strains using the 
DNeasy isolation kit (QIAGEN).  DNA was quantified using a Nanodrop 2000c (Thermo 
Scientific).  qPCR was performed on 1 ng total DNA as previously described [341].  ∆∆Ct values 
for the mitochondrial gene cytochrome C oxidase subunit 1 (CO1) were normalized to the 
nuclear gene NDUFV1.  The CO1 primers were 5- TGCTAGCCGCAGGCATTAC-3 (fwd) and 
5-GGGTGCCCAAAGAATCAGAAC-3 (rev).  The primers for NDUFV1 were 5-
CTTCCCCACTGGCCTCAAG-3 (fwd) and 5-CCAAAACCCAGTGATCCAGC-3 (rev).   
 
2.3.5 RNA isolation and qRT-PCR 
Isolated CD4+ T cells were lysed for RNA in RLT buffer (Qiagen).  RNA was isolated using the 
RNeasy mini kit (Qiagen) and cDNA was synthesized using the RT2 First Strand kit (Qiagen).  
RNA was quantified using a Nanodrop 2000c (Thermo Scientific).  qRT-PCR was performed for 
indicated genes using iQ SYBR Green Supermix and iCycler according to manufacturer’s 
instructions (BioRad).  Cycling parameters were as follows:  5 min at 95°C, 30 s at 95°C, 30 s at 
60°C, 30 s at 72°C (40 cycles of steps 2-4), 1 min at 95°C, and then samples were held at 4°C.  
In order to calculate relative expression, ∆∆Ct values were normalized to expression of the 
control gene Rplo (FWD 5’-GGCGACCTGGAAGTCCAACT-3’; REV 5’- 
CCATCAGCACCACAGCCTTC-3’) [342].  Values were normalized to wildtype controls.  The 
primers for TFAM were 5-AAGTCTTGGGAAGAGCAGATGGCT-3 (fwd) and 5-
AGACCTAACTGGTTTCTTGGGCCT-3 (rev).  The primers for mitochondrial complex I were 
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5-CTTCGGCTTTGTGGCTTTCATGGT-3 (fwd) and 5-
AAAGCCCATCAAGCCTCCTCAGAT-3 (rev).  The primers for the glycolysis associated 
genes were taken from Wang et al. [103].   
 
2.3.6 Cell lysates and Western blotting 
Whole-cell lysates were made by lysing cells in anti-pY lysis buffer (50 mM Tris pH 8.0, 137 
mM NaCl, 10% glycerol, 1% NP-40, 1 mM NaF, 10 µg/ml leupeptin, 10 µg/ml aprotinin, 2 mM 
Na3VO4, and 1 mM PMSF), followed by sonication.  Protein concentration was quantified by 
Bicinchoninic acid protein assay (Thermo Fisher Scientific).  25 µg of protein lysates were 
separated by gel electrophoresis on 8% SDS-PAGE gels.  Western blots were performed as 
previously described [168]  Blots were probed overnight at 4°C with primary antibodies to the 
following targets diluted 1:1000 in 5% BSA in Tris-buffered saline with Tween (TBST): 
pAMPK-α (Thr170) and AMPK (both from Cell Signaling). Secondary anti-rabbit antibody was 
used for detection of primary antibodies (1:2000; Cell Signaling).  Chemiluminescence was 
detected in real time using ECL plus reagent (Amersham Pharmacia Biotech) and the Fujifilm 
LAS-3000 imager.  Blots were analyzed using Multi Gauge software (Fujifilm Life Science).  β-
actin expression served as the loading control (Sigma).      
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2.3.7 Extracellular and intracellular flow cytometry staining 
Cells were harvested and first incubated in FACS buffer (1% BSA in PBS) with Fc Block 
(CD16/CD32; BD Biosciences).  Surface staining was performed at 4°C in FACS buffer with the 
following antibodies:  CD4, CD127, CD44, CD62L, LAG-3 (all from BD Bioscience).  For 
experiments examining thymocyte populations the following antibodies were used:  CD45, CD4, 
CD8, CD25 and CD44 (all from BD Bioscience).  For intracellular staining of PTEN (clone 
A2B1; BD Phosflow) and pAkt (Ser473; clone D9E, Cell Signaling), cells were 
fixed/permeabilized as previously described [343].  For pSTAT5 intracellular staining, cells were 
fixed using the Foxp3/Transcription Factor Fixation/Permeabilization Kit (eBioscience) and 
stained using the pSTAT5-PE Cy7 antibody (Tyr694; clone 47/Stat5(pY694); BD Phosflow).  
Cells were analyzed using a BD LSRII and data were analyzed using FlowJo Software (v10.1).       
 
2.3.8 Adoptive transfers and in vivo antibody blockade 
CD4+ T cells were enriched from spleens of WT.OT-II or Lag3-/-.OT-II animals as described 
above.  Cells were labeled with Violet Proliferation Dye 450 (BD Bioscience) according to 
manufacturer’s instructions and 5.0 x 106 T cells were transferred i.v. into B6.Rag1-/- recipients.  
Recipient animals were sacrificed 10 days post-transfer and transferred cells were recovered 
from spleens using CD4+ T cell enrichment kits (Stem Cell) and analyzed by flow cytometry and 
Seahorse Flux Analyzer.  Cohorts of Rag1-/- recipients were treated with 200µg of either αLAG-
3 (clone C9B7W; BioXCell) or αIL-7Rα (clone A7R34; BioXCell) i.p. every-other day starting 
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the day prior to adoptive transfer.  Control animals received either Rat IgG1 (LAG-3) or Rat 
IgG2a (IL-7Rα) isotype controls.  
 
2.3.9 IL-7 treatment in vitro 
Whole splenocytes were plated and treated with 100 ng/mL rmIL-7 (R&D Systems) or media 
alone for 18 hours as previously described [68].  Glucose uptake was measured as described 
below.  IL-7-induced glucose uptake of CD4+ T cells due to IL-7 treatment was calculated as 
follows: 
recovered glucose uptake = (MFI IL-7 treated) – (MFI Media treated). 
Viability was assessed by flow cytometry by staining for CD4 and 7AAD.  Recovered 
viability due to IL-7 treatment was calculated as follows: 
recovered viability = (% 7AAD+ Media treated) – (% 7AAD+ IL-7 treated). 
 
2.3.10 Plate-bound antibody stimulation 
Isolated B6.WT and B6.Lag3-/-- CD4+ T cells were stimulated with plate-bound αCD3 (0.5 
ug/mL; BD Pharmingen) and αCD28 (1.0 ug/mL; BD Pharmingen) for indicated periods of time 
at 37°C in a 5% CO2 incubator.  Cells were cultured in complete splenocyte medium (4.5 mg/dL 
glucose DMEM (Gibco) supplemented with 10% heat-inactivated fetal bovine serum, 1 mM 
sodium pyruvate (Gibco), 10 mM HEPES buffer (Gibco), 2× non-essential amino acids (Gibco), 
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100 µg/mL gentamicin (Invitrogen Life Technologies), 4 mM L-glutamine (Gibco), and 61.5 µM 
2-ME). 
 
2.3.11 Lactate and IFNγ measurements 
Lactate from in vitro culture supernatants was measured using the Accutrend Plus meter and 
lactate strips (Roche) as previously described [344].  IFNγ was measured by ELISA as 
previously described [168].  ELISAs were read using a SpectraMax M2 microplate reader 
(Molecular Devices), and data were analyzed using SoftMax Pro version 5.4.2 software 
(Molecular Devices). 
 
2.3.12 Glucose uptake assay 
CD4+ T cells were stimulated with plate-bound antibodies for 24-72 hours.  Prior to harvest, 
cultures were incubated with the fluorescent glucose analog 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-
4-yl)Amino)-2-Deoxyglucose (2-NBDG; Invitrogen Life Technologies) at 100 µM for 10 
minutes, and uptake was quenched with PBS as previously described [136].  Cells were stained 
for surface markers CD4 and LAG-3 and analyzed live by flow cytometry using a BD LSR II 
instrument (BD Biosciences).  Samples were analyzed using FlowJo software (v10.1; TreeStar).  
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2.3.13 Statistical analysis 
Data are given as mean values ± SEM, with n indicating the number of independent experiments 
or animals, unless otherwise indicated.  Student’s t-test or One-way ANOVA with Bonferroni 
post-hoc analysis was used where appropriate. A p-value of p<0.05 was considered significant 
for all statistical analyses. 
 
2.4 RESULTS 
2.4.1 LAG-3 regulates the homeostatic expansion of naïve polyclonal and monoclonal 
CD4+ T cells  
Previous reports have shown that global knockout of LAG-3 results in increased proliferation of 
naïve CD4+ T cells in both monoclonal (OT.II) and polyclonal (B6) mouse models [157, 338].  
Both C57Bl/6 and B6.OT.II TCR transgenic animals that lack LAG-3 expression in our colony 
similarly demonstrated increased total number of splenocytes and CD4+ T cells in comparison to 
their wildtype counterparts (Figure 8A and B; p<0.05).  Closer examination of T cell subsets 
(naïve, effector, memory) based on CD62L and CD44 expression indicated that absolute 
numbers of naïve CD4+ T cells differed between knockout and wildtype animals (Figure 8C), 
suggesting that the naïve compartment is the most dependent upon LAG-3-mediated regulation. 
 
 
















Figure 8.  LAG-3 negatively regulates homeostatic expansion of naive CD4+ T cells. 
A.  Total cells per spleen from C57Bl/6 WT and Lag3-/- animals (left panel) and B6. OT.II WT and Lag3-/- animals 
(8-12 weeks of age).  B.  Total CD4+ T cells per spleen.  C.  Absolute numbers of CD4+ T cell subsets from wildtype 
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2.4.2 Naïve CD4+ T cell bioenergetics are regulated by LAG-3 
Recent work has revealed that T cell function and proliferation are tightly coupled to cellular 
metabolic programs.  Specifically, naïve CD4+ T cells rely on a more oxidative metabolic 
program thereby maximizing ATP production for driving basal processes like chemotaxis [49].  
As LAG-3-deficient T cells demonstrated increased homeostatic expansion, and the ability to 
proliferate is highly dependent upon metabolism, we hypothesized that LAG-3 regulates the 
bioenergetic profile of these cells.   
 To assess metabolic differences, naïve wildtype and Lag3-/- OT.II T cells were isolated 
from spleens and analyzed using a Seahorse Flux analyzer.  Results from a mitochondrial stress 
test indicated that Lag3-/- OT-IIs displayed significantly higher oxidative (measured by oxygen 
consumption (OCR)) and glycolytic (measured by extracellular acidification rate (ECAR)) 
metabolisms (Figure 9A-C; p<0.0001).  Additionally, Lag3-/- deficient OT-II T cells presented 
with an increased spare respiratory capacity (SRC), a measure of mitochondrial reserve and 
fitness (Figure 9D; p<0.0001).   
 As naïve CD4+ T cells are known to be more oxidative than glycolytic, compared to 
effector T cells, we calculated the ratio of OCR to ECAR as an indicator of whether these naïve 
T cells were behaving more like effector T cells.  As anticipated, both wildtype and Lag3-/-
deficient OT.II T cells had OCR to ECAR ratios over one, indicative of a more oxidative profile 
(Figure 9E); however, this ratio was significantly higher in the knockout OT.IIs (p<0.01).  These 
results denote that the loss of LAG-3 leads to in enhanced oxidative and glycolytic metabolisms, 
but that these T cells still appear “naïve” from a metabolic standpoint. 
Similar experiments were performed using isolated naïve T cells from C57Bl/6 animals, 
and results indicated that indeed, Lag3-/- polyclonal T cells demonstrated enhanced OCR, ECAR, 
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and SRC as compared to those from wildtype animals (Figure 10A-C; p<0.0001).  OCR to 
ECAR ratios for both sets of T cells were greater than one, consistent with OT.II T cells, 
indicating a propensity for OXPHOS (Figure 10D; p<0.0001).  Together, these findings show 
that metabolic regulation elicited by LAG-3 expression is not unique to TCR transgenic T cells.  
Additionally, they suggest that the augmented metabolic phenotype in Lag3-/- T cells likely 






























































Figure 9. Loss of LAG-3 expression in naïve OT.II cells results in enhanced bioenergetics. 
CD4+ T cells were isolated from whole splenocytes, and immediately assayed in a mitochondrial stress test using a 
Seahorse Flux analyzer.  A.  Representative Seahorse run tracings comparing WT and Lag3-/- OT.IIs.  Basal oxygen 
consumption (OCR; B) and extracellular acidification rate (ECAR; C) were measured prior to oligomycin injection 
(****p<0.0001).  D.  Spare respiratory capacity (SRC) was determined as basal OCR subtracted from maximal 
OCR (****p<0.0001).  E. Basal OCR to ECAR ratio (**p<0.01).  Graphs are of n = 5 independent experiments 
unless otherwise indicated. 
  
















Figure 10.  LAG-3 regulates the metabolic profile of naïve polyclonal CD4+ T cells. 
CD4+ T cells were isolated from B6.WT and B6.Lag3-/- splenocytes, and assayed as described in Figure 4. Basal 
oxygen consumption (OCR; A.) and extracellular acidification rate (ECAR; B) were measured prior to oligomycin 
injection (****p<0.0001).  C.  Spare respiratory capacity (SRC) was determined as basal OCR subtracted from 
maximal OCR (****p<0.0001).  D. Basal OCR to ECAR ratio (****p<0.0001).  Graphs are of n>3. 
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2.4.3 LAG-3 expression negatively regulates mitochondrial biogenesis in naïve CD4+ T 
cells  
Memory CD8+ T cells demonstrate increased SRC, largely due to their increased mitochondrial 
mass and biogenesis, compared to effector T cells [128, 129].  As Lag3-/- OT-IIs displayed a 
similar phenotype (Figure 9), we sought to determine if the enhanced mitochondrial oxygen 
consumption was in part, due to overall increased mitochondrial mass.  PCR analysis revealed 
that Lag3-/- OT.IIs exhibited a 1.5-fold increase in their mitochondrial to nuclear DNA ratio, 
compared to wildtype T cells, indicative of increased mitochondrial mass (Figure 11A; p<0.01).  
qRT-PCR analysis also indicated increased expression of mitochondrial complex I, further 
corroborating the DNA results (Figure 11B; p<0.05).  While DNA and RNA analysis revealed 
increased mitochondrial mass in Lag3-deficient T cells, measurement of forward scatter, as a 
readout of cell size, indicated no difference due to LAG-3 expression (Figure 11C).   
Mitochondrial Transcription Factor A, or TFAM, is a key activator of mitochondrial 
biogenesis, and mRNA analysis revealed a 1.8-fold increase in TFAM expression in Lag3-/- 
OT.IIs compared to wildtype T cells (Figure 11D; p<0.01).  The adenosine monophosphate 
activated protein kinase/Sirtuin-1 (AMPK/Sirt-1) pathway drives activation of the transcription 
factor Peroxisome proliferator-activated receptor gamma coactivator 1-α (PGC-1α), which in 
turn controls TFAM expression [345, 346].  Therefore, it was important to determine whether if 
this pathway was mediating the increased mitochondrial mass observed in Lag3-/- OT.II T cells.  
Protein analysis showed increased activated AMPK, as measured by phosphorylation (Thr172) 
(Figure 11E), concurrent with a two-fold increase in Sirt-1 expression (Figure 11F), suggesting 
that LAG-3-mediated suppression of this pathway likely dampens mitochondrial biogenesis.  
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Similar differences in mitochondrial biogenesis and signaling were observed in 
polyclonal naïve CD4+ T cells (Figure 12A-F).  Yet, while there were observed differences due 
to LAG-3 expression in mitochondrial oxygen consumption (Figure 10) and biogenesis (Figure 
12), there was no significant difference in total ATP production between the two cell types 
(Figure 12G). These studies reveal that LAG-3 expression negatively regulates mitochondrial 
biogenesis by tempering the AMPK/Sirt-1 pathway, thereby also controlling mitochondrial 
































































Figure 11.  LAG-3 expression negatively regulates mitochondrial biogenesis in naive CD4+ T cells.  
Naïve CD4+ T cells were isolated from whole splenocytes and used for downstream analysis.  A.  qPCR for 
measuring mitochondrial (mDNA) to nuclear (nDNA) DNA ratio.  B.  qRT-PCR analysis of mitochondrial Complex 
I expression.  C.  Representative histogram measuring forward scatter (cell size).  D.  qRT-PCR analysis of TFAM 
expression.  E.  Representative Western blots of pAMPK (Thr172), total AMPK, and β actin (loading control).  F.  
qRT-PCR analysis of Sirt-1 expression.  Data are displayed as means ± SEM of n=5-9 independent experiments.  




























Figure 12.  LAG-3 regulates mitochondrial biogenesis in naive polyclonal CD4+ T cells. 
Polyclonal CD4+ T cells were isolated from C57Bl/6 wildtype and Lag3-/- animals and analyzed for mitochondrial 
differences.  A.  qPCR for measuring mitochondrial (mDNA) to nuclear (nDNA) DNA ratio.  mRNA expression of 
B. TFAM and C. mitochondrial complex I.  D.  Measure of cell size by forward scatter (FSC).  E.  Protein analysis 
of activated (phosphorylated; Thr172) and total AMPK.  F.  mRNA expression of Sirt-1.  G.  Measure of 
intracellular ATP per ug of protein.  Data are displayed as means ± SEM of n=7-9 independent experiments.  
*=p<0.05; **=p<0.01.   
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2.4.4 Loss of LAG-3 expression does not alter the frequency of thymocyte populations 
Following the observations that LAG-3 deficiency resulted in enhanced mitochondrial mass 
(Figures 11-12) and metabolism (Figure 9-10), we wanted to further delineate if this phenotype 
was due to alterations in thymic development or extrinsic signaling in the periphery. To examine 
thymic subsets, thymuses were harvested from 4-6-week-old animals, and cells were stained for 
flow cytometry.  Identification of immune cells was based first on CD45 expression and then 
CD8 versus CD4 expression to distinguish double negative (DN), double positive (DP), and 
single positive (SP) populations (Figure 13A).  Additionally, DN populations were further 
dissected into DN subsets 1-4 based on CD44 and CD25 expression.  Overall, Lag3-/- OT.II 
thymuses had greater cellularity compared to those from wildtype animals (Figure 13B; 
p=0.082), suggesting increased proliferation in the thymus.  However, thymic cellularity 
remained relatively unchanged in B6 animals (Figure 13C).  Following flow cytometric analysis, 
there were no differences in frequencies of DN, DP, and SP populations between wildtype and 
LAG-3-/- animals, regardless of strain (Figure 13D).  These results held true for DN 1-4 
populations as well (Figure 13E).  Based on these data, we concluded that it was unlikely LAG-3 
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Figure 13.  Loss of LAG-3 expression does not alter the frequency of T cell precursors in the thymus. 
A.  Flow cytometry gating for examining single and double positive thymocytes from OT.II wildtype and LAG-3-/- 
animals (4-6 weeks old).  Total number of cells per thymus comparing B. WT and LAG-3-/- OT.II and C. B6.WT 
and LAG-3-/- animals.  D.  Frequencies of double negative (DN), double positive (DP), CD4 single positive (CD4 
SP) and CD8 single positive (CD8 SP) populations from indicated strains.  E.  Frequencies of double negative 1-4 
populations based on CD44 and CD25 expression.  F.  LAG-3 surface expression of wildtype OT.II and B6 double 
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2.4.5 LAG-3 signaling is necessary for regulating mitochondrial metabolism in the 
periphery 
As data from thymic populations did not yield significant differences, we next assessed the role 
of LAG-3 extrinsic signaling in the periphery.  To do so, we utilized a model of spontaneous 
homeostatic proliferation, whereby naïve T cells were adoptively transferred into lymphopenic 
animals (Figure. 14A).  To directly assess if LAG-3 mediated an effect, a cohort of animals that 
received wildtype OT.II T cells were treated with a LAG-3 blocking antibody.  After ten days, 
splenic CD4+ T cells were analyzed by flow cytometry and results showed a higher percentage of 
CD4+ T cells per spleen in animals that received Lag3-/- OT.II T cells (Figure 14B; p<0.05).  
Additionally, Lag3-/- OT.II T cells proliferated to a greater extent, as measured by Cell Trace 
Violet dilution (Figure 14C; p<0.05).  Treatment of WT T cells with a LAG-3 blocking antibody 
fully restored the total percentage and proliferation of transferred T cells to levels demonstrated 
by LAG-3-deficient cells (Figure 14B-C).  Thus, LAG-3 signaling directly regulates homeostatic 










  77 
 
Figure 14.  LAG-3 loss and blockade result in increased homeostatic expansion following adoptive transfer.   
A.  Schematic of adoptive transfer model to assess homeostatic expansion.  A cohort of WT OT.II recipients also 
received 200µg of αLAG-3 i.p. every-other-day.  B.  Percentage of CD4+ T cells per spleen and C. percent 
proliferation normalized to WT OT.II assessed by flow cytometry.  Proliferation was determined by Cell Trace 
Violet dilution as compared to non-transferred controls.  Data are presented as means ± SEM of 3 independent 
experiments with n=3-5 mice per experiment.  *=p<0.05 
 
 
Splenic OT.II T cells from recipient animals were also isolated and analyzed for 
mitochondrial fitness by Seahorse assay.  Similar to what was demonstrated in ex vivo analysis 
(Figure 9-10), OT.II T cells deficient in LAG-3 displayed significantly higher basal OCR and 
ECAR as compared to their wildtype counterparts (Figure 15A-D).  LAG-3 blockade by 
monoclonal antibody administration augmented both OCR and ECAR of WT cells to levels 
comparable to Lag3-/- CD4+ T cells, demonstrating an extrinsic inhibitory effect of LAG-3 on 
mitochondrial and glycolytic metabolism (Figure 15A-D).  Interestingly, SRC was completely 
absent in T cells from all three cohorts (Figure 15E) in comparison to values obtained during ex 
vivo analysis (Figure 9D, 10C).  When we compared basal OCR and SRC levels pre-transfer 
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with basal OCR rates post-transfer, we observed an additive effect – the post-transfer basal OCR 
was equal to the sum of the pre-transfer basal OCR and SRC (Figure 15F).  These results suggest 
that SRC was not lost, but was in fact being utilized to support spontaneous proliferation.   These 
data reveal that LAG-3 engagement and signaling act to limit naïve CD4+ T cell proliferation by 














































































Figure 15.  LAG-3 tempers T cell bioenergetic pathways during homeostatic expansion. 
OT.II WT and Lag3-deficient T cells were adoptively transferred into B6.Rag1-/- recipients as a model of 
homeostatic expansion.  A cohort of WT recipients were treated with 200ug of a LAG-3 blocking antibody. A-B.  
Representative Seahorse analysis of isolated OT.II T cells 10 days post-adoptive transfer.  Calculated C. basal OCR, 
D. ECAR, and E. SRC of OT.II T cells post-transfer (****p<0.0001).  F.  Comparison of post-transfer basal OCR to 
sum of pre-transfer OCR and SRC.  Values are indicative of combined n>5 animals per group and displayed as 
mean ± SEM.    
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2.4.6 LAG-3 expression increases the dependence of naïve CD4+ T cells on Interleukin-7 
The common gamma chain (γc) family of cytokines (IL-7, IL-15, IL-2, IL-9 and IL-4) play 
important roles in the homeostasis and proliferation of naïve, effector and memory T cells [74, 
79, 347, 348].  In the context of naïve T cell homeostasis and survival, IL-7 is essential for 
mediating both glucose uptake and oxidation, and survival via Bcl-2 expression [66-68, 91].  
Moreover, IL-7 mediates its signaling via Akt and STAT5 phosphorylation.  Following the 
findings that LAG-3 loss resulted in increased mitochondrial oxidation, homeostatic proliferation 
(Figure 14-15), and STAT5 phosphorylation, all responses that are IL-7 dependent [66-68, 91], 
we wanted to assess if this enhancement was due to increased IL-7 signaling.   
Examination of CD127 (IL-7Rα) expression in adoptive transfer experiments revealed 
that LAG-3-deficient OT.IIs exhibited an approximate 25% decrease in CD127 surface 
expression compared to WT T cells both pre- and post-transfer (Figure 16A-B; p<0.05).  Work 
by Park et al. showed that increased IL-7/IL-7R signaling is indirectly related to IL-7 mRNA 
and surface expression [85].  Our results, coupled with the studies from Park et al., suggested 
that LAG-3-deficient T cells experience increased IL-7R signaling, resulting in reduced surface 
expression.  To directly test the influence of IL-7 on naïve T cell responses, wildtype and Lag3-/- 
OT.II splenocytes were treated with either media alone or media containing IL-7 for 18 hours 
and assessed for glucose uptake and viability.  Alternatively, to what was anticipated, wildtype 
OT.II T cells exhibited a significantly higher change in glucose uptake (Figure 16C-D; p<0.05) 
and viability (Figure 16E-F) due to the presence of IL-7 as compared to Lag3-/- T cells, thus 
suggesting wildtype T cells have a greater dependence on the cytokine.  Additionally, the 
increased CD127 expression by these T cells also suggests an increased IL-7 dependence. 
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Figure 16.  Loss of LAG-3 expression reduces sensitivity to IL-7 in vitro. 
Relative IL-7Rα surface expression on naïve CD4+ wildtype and LAG-3-/- T cells A. pre- and B. post- adoptive 
transfer.  C-E.  Naïve splenocytes were treated with or without IL-7 in vitro for 18 hours.  C.  Representative 
histograms of glucose uptake (2-NBDG) of naïve CD4+ T cells treated with IL-7 or media alone (control).  D.  
Change in glucose uptake due to the presence of IL-7.  E.  Representative dot plots of 7AAD staining of CD4+ T 
cells to measure viability.  F.  Percent recovered viability due to the presence of IL-7 in cell cultures.  Data were 
normalized to WT values within experiments and are displayed as mean ± SEM of n = 5-6 independent experiments.  




2.4.7 LAG-3-deficient T cells are refractory to IL-7 deprivation during homeostatic 
proliferation 
Following the in vitro studies, we sought to verify our findings in our in vivo adoptive transfer 
model.  To do so, Rag1-/- recipients were treated i.p. with either a CD127 blocking antibody or an 
isotype control every other day throughout the course of the experiment.  Ten days post-transfer 
wildtype and Lag3-/- OT.II cells were recovered from spleens and analyzed by flow cytometry 
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and Seahorse as described above.  Metabolic analysis revealed that even with IL-7 blockade, 
Lag3-/- OT.II T cells outperformed treated wildtype cells during a mitochondrial stress test 
(Figure 17A).  In comparison to isotype treated controls, IL-7 blockade resulted in a 60% 
reduction in basal OCR of wildtype cells (Figure 17B; p=0.0544); however, Lag3-/- T cells 
experienced no change in basal OCR (Figure 17C), indicating an IL-7 dependence for OCR in 
wildtype T cells.  Similar to previous experiments, all transferred T cells, regardless of treatment, 
used the entirety of their SRC to drive homeostatic expansion (Figure 17D).  Unlike oxygen 
consumption, there was no dependence on IL-7 for glycolysis in either cell type, yet there was a 
trend that IL-7 blockade increased glycolysis in wildtype T cells (Figure 17E,F).  This could 
indicate that without the use of oxidative phosphorylation, wildtype T cells may try to 
compensate by increasing their dependence on glycolysis.  These metabolic differences also 
directly correlated with overall percentages of T cells per spleen of recipient animals (Figure 
17G; p<0.05).  Lastly, IL-7 is known to regulate naïve T cell size, and cell size analysis by 
forward scatter indicated that WT T cells demonstrated a greater reduction in cell size between 
those deprived of IL-7 and those treated with IgG control (Figure 17H-I).  Lag-3 deficient T cells 
exhibited little to no change in forward scatter due to IL-7R blockade (Figure 17H-I).   
 
 














































Figure 17. LAG-3-deficient CD4+ T cells are refractory to IL-7 deprivation in vivo. 
A. OCR (left panel) and ECAR (right panel) of OT.II T cells following adoptive transfer and treatment with 
αCD127 or isotype control antibody.  Basal relative OCR of B. WT T cells and C. LAG-3-/- OT.II T cells ± antibody 
treatment.  D.  Spare respiratory capacity of T cells following adoptive transfer.  Relative ECAR of E. WT and F. 
Lag3-/- OT.II T cells ± antibody treatment.  G.  Percent CD4+ T cells per spleen 10 days post adoptive transfer.  H.  
Representative histograms of forward scatter (FSC) of adoptively transferred CD4+ T cells.  I.  Quantification of 
forward scatter of CD4+ T cells as calculated by FlowJo software.  *=p<0.05; ***=p<0.001.    
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2.4.8 Inhibition of STAT5 by LAG-3 stabilization of PTEN restrains homeostatic 
expansion  
Previous studies have indicated that LAG-3 engagement results in inhibitory downstream 
signaling, with implications on proliferation and cytokine production [156, 337, 349, 350].  
While the particular domain in the LAG-3 cytoplasmic tail that elicits this inhibitory effect has 
been identified [145], the exact downstream signaling of the molecule remains elusive.  Work by 
Durham et al. indicated that LAG-3 engagement can inhibit phosphorylation of STAT5, 
resulting in dampened T cell homeostatic expansion [338].  Moreover, activated STAT5 is 
critical for homeostatic expansion [83, 84], and upon activation, can translocate to the 
mitochondria and bind mitochondrial DNA, potentially modulating mitochondrial gene 
transcription [351, 352].  These findings suggest a link between STAT5 and regulation of 
mitochondrial respiration and biogenesis.  Studies in our adoptive transfer model further 
confirmed that LAG-3 inhibition via knockout or antibody blockade resulted in increased STAT5 
phosphorylation in CD4+ T cells (Figure 18A; p<0.05).   
The PI3/Akt pathway has also been shown to be critical for driving naïve and memory T 
cell homeostatic proliferation and increased mitochondrial respiration [353, 354]; therefore, we 
next examined Akt activation in our model.  Intracellular staining for phosphorylated Akt in 
naïve CD4+ T cells showed very modest increases in both WT + anti-LAG-3 Ab. and LAG-3-/- T 
cells compared to WT OT.IIs; however, these differences were not significant (Figure 18B).  
These results were not entirely surprising as Akt is critical for mediating homeostatic 
proliferation, which WT OT.II T cells do exhibit, and could also be activated to serve as a 
survival signal in these T cells.  
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 Next, we investigated if elevated STAT5 phosphorylation in Lag3-/- T cells could be due 
to decreased expression of inhibitory phosphatases.  Specifically, we targeted PTEN, as it is 
stabilized by another inhibitory receptor, Programmed Cell Death-1 (PD-1), and its stabilization 
can alter T cell metabolic programming [355, 356].  Additionally, PTEN knockout cells 
demonstrate hyperproliferation [86, 89], reminiscent of the enhanced proliferation exhibited by 
LAG-3-deficient CD4+ T cells (Figures 8, 14).  As anticipated, WT OT.II T cells showed 
increased PTEN expression as measured by flow cytometry, and LAG-3 knockout resulted in 
approximately a 20% reduction in PTEN levels (Figure 18C; p<0.01).  Overall, these results 





Figure 18. Signaling via LAG-3 stabilizes PTEN expression. 
Intracellular Phospho-flow staining of adoptively transferred CD4+ T cells for A. pSTAT5 (Tyr964), B. pAkt 
(Ser497) and C. PTEN.  Mean fluorescence intensity (MFI) of CD4+ T cells was calculated using FlowJo software, 
and numbers were normalized to WT values to measure relative expression. Data are presented as means ± SEM of 
n=5-7 animals. *=p<0.05, **=p<0.01.     
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2.4.9 Loss of LAG-3 expression results in enhanced aerobic glycolysis and effector 
function during activation 
One of the key characteristics of memory T cells is their rapid activation upon secondary 
challenge [137], which is due, in part, to their increased SRC and mitochondrial content [128, 
129].  As our data indicated that LAG-3-/- CD4+ T cells demonstrated a more memory-like 
phenotype metabolically (Figures 9 and 11), we hypothesized that this bioenergetic advantage 
would enable a faster transition to effector function.  LAG-3 is known to be upregulated to the T 
cell surface during activation [149, 150], and ligation by MHC class II, results in diminished 
proliferation and effector function [337, 349].  Therefore, we utilized an APC-free system to 
circumvent any regulation in the wildtype cells due to LAG-3 engagement.   
During activation, T cells undergo robust metabolic preprogramming, transitioning from 
OXPHOS (naïve) to aerobic glycolysis (effector) [48].  This transition is critical for supporting 
increased macromolecule synthesis during both clonal expansion and effector function.  Work 
from Wang et al. demonstrated that within 24 hours post-activation, CD4+ T cells upregulate the 
necessary genes required for the metabolic transition to aerobic glycolysis [103].  At 24 hours 
post-stimulation in our model, Lag3-/- CD4+ T cells exhibited significantly greater upregulation 
of the transcription factors Myc and Hif1α (Figure 19A, p<0.05), which orchestrate upregulation 
of the glycolytic pathway [49].  Lag3-/- T cells also more highly upregulated the passive glucose 
transporter Glut1, which is necessary for importing glucose into CD4+ T cells (Figure 19A; 
p<0.05) [357].  With increased Glut1 upregulation by LAG-3-deficient T cells, we next 
examined glucose uptake by these cells.  Indeed, Lag3-/- T cell cultures had a higher percentage 
of glucosehi (2-NBDGhi) T cells at both 48 and 72 hours post-stimulation (Figure 19B-C), 
indicative of more T cells transitioning to aerobic glycolysis.  Lastly, lactate secretion, the 
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byproduct of aerobic glycolysis was greater in Lag3-/- T cell supernatants (Figure 19D; p<0.01), 
signifying enhanced usage of this pathway.   
Lag3-/- CD4+ T cells also showed greater cell growth during activation, as measured by 
forward scatter (Figure 19E), a process that is necessary for supporting cell division.  IFNγ 
production is directly regulated by transition to aerobic glycolysis [358], and based on these data 
we hypothesized that due to their enhanced aerobic glycolysis, Lag3-/- T cells would produce 
more IFNγ as compared to their wildtype counterparts.  Indeed, IFNγ ELISA results from culture 
supernatants revealed that LAG-3-deficient T cells produced three times as much IFNγ as 
wildtype T cells at both 24 and 48 hours post-stimulation (Figure 19F; p<0.05).  Lastly, LAG-3 
is highly upregulated to the T cell surface upon activation, and can therefore, serve as a marker 
of activation.  Further examination of wildtype cells indicated that LAG-3 expression correlated 
with glucose uptake, as LAG-3hi T cells demonstrated higher 2-NBDG fluorescence (Figure 
19G), suggesting that LAG-3 may serve as a marker for more glycolytic effector T cells.     
Overall, these data suggest that the enhanced mitochondrial bioenergetics due to loss of 
LAG-3 expression support heightened upregulation of aerobic glycolysis during activation, 






















































Figure 19.  LAG-3-deficient CD4+ T cells demonstrate enhanced aerobic glycolysis and effector function 
upon activation. 
A.  qRT-PCR measuring expression of glycolysis-associated genes.  B-C.  Glucose uptake of CD4+ T cells 
measured by 2-NBDG fluorescence.  D.  Lactate secretion in culture supernatants.  E.  Forward scatter of CD4+ T 
cells 48 hours post-stimulation.  F.  IFNγ secretion in culture supernatants.  G.  Representative dot plot of LAG-3 by 
2-NBDG uptake of CD4+ T cells during activation.  Data are presented as means ± SEM of combined n=5-9 
independent experiments.  *=p<0.05, **=p<0.01, ***=p<0.001.  
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2.5 DISCUSSION 
Our results here indicate that expression of LAG-3 on naïve CD4+ T cells regulates 
mitochondrial biogenesis and metabolism, as a means of controlling homeostatic expansion and 
quiescence.  While LAG-3 expression on naïve CD4+ T cells is known to be rather low as 
compared to activated or exhausted T cells, it is clear that the expression levels are sufficient for 
mediating phenotypic alterations [157, 338].  The enhancement of mitochondrial metabolism and 
mass due to lack of LAG-3 expression is consistent with the recent study published by Scharping 
et al [343].  Their results showed that increased expression of inhibitory receptors (PD-1, LAG-3 
and Tim-3) on exhausted intratumoral CD8+ T cells correlated with reduced mitochondrial mass, 
further supporting a link between these receptors and the mitochondria.   
The fact that antibody blockade of LAG-3 on wildtype CD4+ T cells during adoptive 
transfer experiments yielded similar proliferation and metabolic responses as LAG-3-/- cells 
(Figures 10-11), suggests that this phenotype is not solely due to an intrinsic mechanism.  Rather, 
that extrinsic signals, potentially via MHC class II:LAG-3 interactions, drive inhibitory signaling 
pathways that dampen AMPK-driven mitochondrial biogenesis.  This is also supported by 
finding that there were no differences in frequency of double negative (DN1-4), double positive 
and single positive populations in the thymus (Figure 13), again suggesting that this phenotype is 
not a product of thymic developmental alterations, but rather alterations due to T cell interactions 
in the periphery.     
We had initially hypothesized that LAG-3 may inhibit tonic TCR signaling that occurs in 
the periphery to maintain survival of naïve CD4+ T cells.  During tonic signaling, naïve T cells 
are engaged by MHC-presented self-peptides by antigen presenting cells as a means of initiating 
low-level TCR signaling.  This tonic signal can be sufficient to increase anti-apoptotic Bcl-2 
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expression and allow T cells to enter the cell cycle to facilitate homeostatic expansion.  Fine 
tuning of this signal is critical for preventing overt T cell activation; therefore, inhibitory 
mechanisms, like CD5 expression, are in place to modulate TCR signaling [96, 359].  Thus, we 
hypothesized that LAG-3-/- CD4+ T cells would express more CD5, indicative of more tonic TCR 
signaling; however, our data showed no appreciable differences in CD5 expression between 
naïve wildtype and LAG-3-deficient T cells, even after adoptive transfer (data not shown).  This 
result does not completely rule out the hypothesis that LAG-3 regulates tonic signaling; however, 


























Figure 20. Mechanism for LAG-3's regulation of mitochondrial respiration and homeostatic expansion. 
We propose that LAG-3 expression on naïve CD4+ T cells stabilizes PTEN expression, thereby resulting in 
dephosphorylation of STAT5 and Akt, resulting in basal proliferation and mitochondrial respiration.  In order to 
overcome this inhibition, strong IL-7 signaling is required to then drive sufficient Akt and STAT5 activation to 
mediate homeostatic proliferation and mitochondrial oxidation. 
 
 











Figure 21. Absence of LAG-3 results in destabilization of PTEN and its inhibitory function. 
In the absence of LAG-3, PTEN expression is destabilized thereby allowing greater downstream TCR signaling.  
This enhancement allows for more robust Akt and STAT5 activation, resulting in greater homeostatic proliferation 
and enhanced mitochondrial respiration.  This increased signaling reduces the requirement for IL-7 signaling to 
mediate these processes. 
 
Activated Lag3-/- CD4+ T cells demonstrated enhanced aerobic glycolysis and effector 
function (Figure 19).  Interestingly, memory T cells demonstrate similar enhanced activation in 
comparison to naïve T cells, in part, due to their enhanced mitochondrial mass and SRC [128, 
129].  We propose that the bioenergetic advantage exhibited by Lag3-/- CD4+ T cells supports 
their enhanced activation and glycolytic potential, similarly.  Following activation, it is necessary 
for a subset of activated effector T cells to survive as long-lived memory T cells.  Metabolically, 
this transition is dependent upon the ability of the cell to downregulate aerobic glycolysis and 
transition back to a more oxidative phenotype.  Enhancement of OXPHOS via treatment with 
Metformin, an AMPK activator, resulted in an increased frequency of memory T cells following 
activation [136].  As LAG-3-deficient T cells are much more glycolytic than wildtype cells, we 
might suspect that they would have a more difficult time converting back to oxidative 
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phosphorylation; thus, limiting the potential for generating memory T cells.  Studies by 
Workman et al. indicated increased numbers of virus-specific memory CD4+ and CD8+ T cells 
30 days post-infection in Lag3-/- animals [336].  However, re-challenge experiments to assess 
memory T cell functionality were not performed; therefore, while numbers may indicate an 
advantage, there may be functional deficiencies due to LAG-3 loss.  Further studies would be 
necessary to more fully assess memory T cell generation.    
In the context of autoimmunity, LAG-3 has been shown to play a critical role in 
suppressing CD4+ T cell function.  Global knockout and antibody blockade of LAG-3 in non-
obese diabetic (NOD) animals accelerated autoimmune Type 1 Diabetes progression [155, 158].  
Moreover, animals with genetic LAG-3 alterations that resulted in accelerated T1D had equally 
functional regulatory T cell populations, indicating that this disease progression was not due to 
dysfunctional peripheral tolerance [158].  Our data imply that the increased T1D progression in 
NOD.LAG-3-/- animals was due, in part, to metabolic enhancement of naïve CD4+ T cells, 
conferring greater activation and disease-inducing potential.  Human studies have been 
conducted to identify single nucleotide polymorphisms (SNPs) in genes that are associated with 
susceptibility to autoimmune diseases.  A study by Zhang et al. identified SNPs in both the genes 
encoding LAG-3 and IL-7R that are more highly associated with progression to multiple 
sclerosis [360].  This work strengthens our conclusion that there is an inherent link between 
LAG-3 and IL-7R expression and signaling, which could contribute to autoimmunity.  Based on 
these studies and our work, future studies of human autoimmune-associated T cells with LAG-3 
mutations may indicate metabolic alterations that could contribute to pathogenicity. 
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The immune system is necessary for protecting against various pathogens.  However, under 
certain circumstances, self-reactive immune cells can drive autoimmunity, like that exhibited in 
type 1 diabetes (T1D).  CD4+ T cells are major contributors to the immunopathology in T1D, and 
in order to drive optimal T cell activation, third signal reactive oxygen species (ROS) must be 
present.  However, the role ROS play in mediating this process remains to be further understood.  
Recently, cellular metabolic programs have been shown to dictate the function and fate of 
immune cells, including CD4+ T cells.  During activation, CD4+ T cells must transition 
metabolically from oxidative phosphorylation to aerobic glycolysis to support proliferation and 
effector function.  As ROS are capable of modulating cellular metabolism in other models, we 
sought to understand if blocking ROS also regulates CD4+ T cell activation and effector function 
by modulating T cell metabolism.  To do so, we utilized an ROS scavenging and potent 
antioxidant manganese metalloporphyrin (MnP).  Our results demonstrate that redox modulation 
during activation regulates the mTOR/AMPK axis by maintaining AMPK activation, resulting in 
diminished mTOR activation and reduced transition to aerobic glycolysis in diabetogenic 
splenocytes.  These results correlated with decreased Myc and Glut1 upregulation, reduced 
glucose uptake, and diminished lactate production.  In an adoptive transfer model of T1D, 
animals treated with MnP demonstrated delayed diabetes progression, concurrent with reduced 
CD4+ T cell activation. Our results demonstrate that ROS are required for driving and sustaining 
T cell activation-induced metabolic reprogramming, and further support ROS as a target to 
minimize aberrant immune responses in autoimmunity. 
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3.2 INTRODUCTION 
Type 1 diabetes (T1D) is an autoimmune disease where self-reactive T cells escape into the 
periphery and target pancreatic β cells for destruction. While T1D progression results from the 
interplay between various immune cell types, CD4+ T cells are considered the principal 
contributor to disease pathology [12, 361].  We and others have demonstrated that reactive 
oxygen species (ROS) play an important role in driving the immunopathology exhibited in T1D 
[16, 206].  Antigen presenting cells (APCs), like macrophages [223], and CD4+ T cells [225] 
express functional NADPH oxidases (NOX) which generate ROS upon APC-induced T cell 
activation.  Both NOX [202] and mitochondrial-derived ROS from the T cell itself [244] are 
necessary for optimal CD4+ T cell activation. These ROS, with cytokines, serve as the third 
signal, during T cell activation.  In combination with T cell receptor (TCR; signal 1) and co-
stimulatory molecule (signal 2) engagement, these three signals enable cell cycle entry [212] and 
effector function acquisition [202].  
Recently, interest has grown in understanding the role of cellular metabolism in fulfilling 
the objectives of T cell activation and effector function.  Under homeostatic conditions, naïve 
CD4+ T cells remain relatively quiescent and rely predominantly on oxidative phosphorylation 
(OXPHOS) to meet basal metabolic needs [362].  Upon antigen (e.g. β cell-derived antigens in 
T1D) encounter, naïve CD4+ T cells become activated and have two main goals – to clonally 
expand and to differentiate into effector T cells. To meet these goals during activation, CD4+ T 
cells undergo dynamic metabolic reprogramming by transitioning to aerobic glycolysis [49, 50, 
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362], also known as the Warburg Effect, which was first characterized in tumors [29, 50]. The 
utilization of aerobic glycolysis by activated CD4+ T cells supports increased macromolecule 
biosynthesis, aiding in daughter cell formation and effector molecule production, along with 
more rapid production of ATP as compared to OXPHOS [49, 50, 362].   
In both tumors and T cells, Myc is a predominant player in coordinating increased 
glycolysis and cell proliferation [29, 46, 103, 363]. Upstream, activation of mammalian target of 
rapamycin (mTOR) signaling is critical for Myc expression and thus aerobic glycolysis, as 
treatment with the mTOR inhibitor rapamycin results in dampened lactate production, 
proliferation, and cytokine production in CD4+ T cells [364, 365].  In contrast, AMP-activated 
protein kinase (AMPK) is a known inhibitor of mTOR and is responsible for enhancing oxidative 
metabolism to restore the ATP to AMP ratio [366, 367].  Overexpression of AMPK in tumors 
inhibits the Warburg Effect, whereby tumors demonstrate reduced size and lactate production 
[368].  Similarly, AMPK activation in T cells results in reduced mTOR activation, diminished 
effector differentiation, and hyporesponsiveness [369].  These results highlight that the interplay 
between mTOR and AMPK strongly dictates T cell metabolic and functional outcome.      
Highly proliferative cells in various models demonstrate enhanced aerobic glycolysis, 
indicating its requirement for sustaining rapid division.  Targeting tumor metabolism via the use 
of glycolytic inhibitors like 2-deoxyglucose, have proven to be effective in reducing tumor 
burden and metastasis [370]. The efficacy of metabolic modulation in cancer, and the metabolic 
similarities between proliferating tumor cells and effector CD4+ T cells, indicate a potential 
avenue for controlling aberrant T cell responses (like those in autoimmunity) by targeting T cell 
metabolism.  Indeed, others have demonstrated potential for ameliorating autoimmunity by 
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metabolic manipulation [188]; however, there remains a large gap in understanding the 
mechanisms by which specifically T cell metabolism is controlled. 
Additionally, many metabolic regulators demonstrate redox sensitivity, including the 
transcription factors HIF-1α [370] and NF-κB [371], and AMPK [372], to name a few, 
underscoring the potential for redox regulation in modulating metabolism.  We and others have 
shown that a manganese metalloporphyrin, Mn(III) meso tetrakis (N -alkylpyiridinium-2-yl) 
porphyrin, or MnP, is capable of scavenging ROS (i.e. hydrogen peroxide and superoxide) [373, 
374], inhibiting lipid peroxidation [375], and performing redox reactions in cellular systems 
[324, 376].  As T1D is known to be driven by increased oxidative stress [16, 207], our laboratory 
has demonstrated that inhibition of ROS during immune activation results in dampened CD4+ T 
cell responses, thus inhibiting T1D progression [168, 199, 304, 326].  Specifically, work by 
Delmastro-Greenwood et al. showed that treating NOD.BDC.2.5.TCR-Tg mice with MnP in 
vivo for 7 days resulted in increased glucose oxidation and aconitase activity in naïve 
splenocytes, indicative of enhanced OXPHOS, the predominant pathway used by naïve immune 
cells [328].  While these studies did demonstrate metabolic alterations due to MnP treatment, 
they were conducted using naïve immune cells that had no prior exposure to their cognate 
antigen.  As previously stated, T cell metabolic reprogramming occurs only during antigen-
mediated activation; therefore, we sought to expand our understanding of the role of ROS and 
metabolism during such activation events. 
Based on these previous studies, we hypothesized that redox modulation by MnP during 
CD4+ T cell activation would inhibit the transition to aerobic glycolysis, and thus, minimize 
proliferation and effector function.  Our data demonstrate that MnP treatment resulted in reduced 
Myc upregulation, glycolytic enzyme expression, and lactate production, collectively indicating 
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inhibition of aerobic glycolysis.  These results were in part due to diminished mTOR signaling.  
Interestingly, redox modulation enhanced activation of the mTOR inhibitor, AMPK, due to 
MnP’s high antioxidant activity.  These data show that redox modulation inhibits the metabolic 
transition of CD4+ T cells by maintaining active AMPK and thus resulting in reduced mTOR 
signaling and Myc expression.  These findings support that ROS are required during the 
transition from OXPHOS to aerobic glycolysis during T cell activation, and that disruption of 
ROS may serve as a viable target for modulating immune cell bioenergetics in autoimmune 
diseases like T1D. 
 
3.3 MATERIALS AND METHODS 
3.3.1 Animal models 
Non-obese diabetic (NOD) BDC2.5.TCR.Tg and NOD.scid mice were maintained in the Rangos 
Research Center animal facility of the Children’s Hospital of Pittsburgh.  Animal experiments 
were approved by the Institutional Animal Care and Use Committee (IACUC) of Children’s 
Hospital of Pittsburgh (Assurance Number A3187-01) and were in compliance with the laws of 
the United States of America.  NOD.BDC2.5.TCR.Tg mice were sacrificed at 8-10 weeks of age 
for in vitro experiments.  In this animal, all CD4+ T cells recognize epitopes formed by covalent 
cross-linking of proinsulin peptides and Chromogranin A (CHgA) in beta cell secretory granules.  
These T cells can be stimulated with a known peptide mimotope HRPI-RM that has been 
previously described [377], thus allowing us to examine the effects of MnP on an antigen-
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specific immune response physiologically relevant to T1D.  NOD.scid animals, 6-8 weeks of 
age, were used for adoptive transfer experiments. 
 
3.3.2 Mn(III) meso tetrakis (N-alkylpyiridinium-2-yl) porphyrin 
Mn(III) meso tetrakis (N -alkylpyiridinium-2-yl) porphyrin (MnP) was a generous gift from Dr. 
James Crapo, MD at National Jewish Health (Denver, CO).  MnP was used at a concentration of 
68 µM for in vitro experiments and a 10 mg/kg dose in all animal experiments. 
 
3.3.3 Splenocyte homogenization 
NOD.BDC.2.5.TCR-Tg spleens were harvested and homogenized into single cell suspensions as 
previously described [168], and red blood cells were lysed using red blood cell lysis buffer 
(Sigma). CD4+ T cells were stimulated with their cognate peptide, mimotope 
(EKAHRPIWARMDAKK), at 0.05 uM, with or without MnP in complete splenocyte medium 
[202].  Splenocytes plated with media alone served as negative controls.  Cells were collected for 
downstream analysis at 24-72 hours post-stimulation.  Supernatants were collected for ELISA 
and lactate measurements. 
 
  100 
3.3.4 CD4+ T cell isolation and antibody stimulation 
CD4+ T cells were isolated from whole NOD splenocytes by magnetic bead separation using 
mouse CD4 MicroBeads (Miltenyi) as per manufacturer’s instructions.  Purity was assessed by 
flow cytometric staining pre- and post-isolation.  For antibody stimulation, tissue culture plates 
were coated with αCD3 (0.5 µg/mL) and αCD28 (1.0 µg/mL) in phosphate buffered saline for 2 
hours at 37°C, 5% CO2.  The antibody solution was decanted and CD4+ T cells were plated at 
5.0x105 cells per well of a 96 well, flat-bottom plate, with or without 68 µM MnP.  Unstimulated 
T cells served as negative controls.       
 
3.3.5 ROS and viability assays 
NOD or NOD.BDC.2.5 splenocytes were incubated in media alone or media with 68 µM MnP 
for 2 hours at 37°C.  Cells were washed extensively in cold Hank’s Balanced Salt Solution 
(HBSS) and added to flow tubes at 1.0x106 per tube.  Dihydroethidium (DHE; Molecular Probes) 
or MitoSOX Red (Molecular probes) was diluted per manufacturer’s instructions, and cells were 
treated with a final concentration of 50 µM for 20 minutes (DHE) or 5 µM for 15 minutes 
(MitoSOX) at 37°C.  PMA (500 ng/mL) and ionomycin (500 µg/mL) were added to the tubes 
and incubated at 37°C for indicated periods of time.  Cells were read on an LSRII (BD 
Bioscience).  DHE was read in the AmCyan channel using a 585/42 detector and 545LP filter, 
and MitoSox Red was detected in the PE channel.  Mean Fluorescence Intensity (MFI) was 
determined using FlowJo Software (v10.1). Dye loaded, unstimulated control cells were used to 
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determine background fluorescence, which was subtracted from stimulated values and graphed 
as change in MFI due to stimulation (delta MFI).  Viability was assessed by 7AAD staining (BD 
Biosciences) as per manufacturer’s instructions.  Surface staining for CD4 was performed prior 
to 7AAD staining.  Viability was determined as the percentage of 7AAD negative cells.     
   
3.3.6 Protein lysates and Western blotting 
Following stimulation, cells were harvested, washed with phosphate buffered saline (PBS), and 
sonicated in anti-pY lysis buffer (50 mM Tris pH 8.0, 137 mM NaCl, 10% glycerol, 1% NP-40, 
1 mM NaF, 10 µg/ml leupeptin, 10 µg/ml aprotinin, 2 mM Na3VO4, and 1 mM PMSF). Protein 
concentration was determined by Bicinchoninic acid protein assay (Thermo Fisher Scientific).  
25 µg of protein per sample were boiled in 6x Lammaeli buffer (BIORAD) for 5 minutes and 
separated SDS-PAGE gels.  Samples were then transferred to PVDF membranes for 1-3 hours in 
3% MeOH Tris-Glycine Transfer buffer (BIORAD).  Western blots were blocked in 5% non-fat 
dry milk in Tris-buffered Saline with 1% Tween-20 (TBST).  Blots were probed with the 
following antibodies in 5% BSA/TBST overnight at 4°C:  Myc, pmTOR (Ser2448), total mTOR, 
p4E-BP1 (Thr70), pAMPK-α (Thr170), total AMPK, PFKFB3, p27 Kip1, and Cyclin D3 at 
1:1000 (Cell Signaling), and Glut-1 (1:2000; Abcam).  Blots were either probed with anti-rabbit 
secondary antibody (Cell Signaling; 1:2000) or goat anti-rabbit secondary antibody (Jackson 
Laboratories; 1:10,000) in 5% non-fat dry milk/TBST at RT for 1 hour.  β-actin (Sigma) 
expression was used as a loading control.  Protein expression was detected by 
chemilumenescence using ECL Plus reagent (Amersham Pharmacia Biotech) and the Fujifilm 
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LAS-3000 Imaging system (FujiFilm Technologies).  Multi Gauge software was used to process 
images (Fujifilm Life Science).  Beta-actin expression served as a loading control.       
 
3.3.7 Flow cytometric analysis        
Cells were harvested following stimulation and incubated with Fc block (CD16/CD32; BD 
Biosciences) prior to staining for flow cytometry.  Extracellular staining was performed at 4°C 
using CD4-APC or CD4-FITC (BD Biosciences) in FACS buffer (1% BSA in PBS).  For cellular 
proliferation measurements, splenocytes were stained with 1 µM carboxyfluorescein 
succinimidyl ester (CFSE; Invitrogen) in PBS at 37°C for 15 minutes and isolated CD4+ T cells 
were labeled with Cell Proliferation Dye Violet (BD Bioscience) as per manufacturer’s 
instructions.  Cells were extensively washed with PBS, plated for stimulation, and surface 
stained after harvest.  
For cell cycle analysis, cells were fixed and permeabilized in 70% cold EtOH for 20 
minutes on ice following stimulation and stored at 4°C until staining for flow analysis.  Cells 
were washed with ice cold PBS two times to remove residual EtOH, and surfaced stained for 
CD4 as described above.  After RNase treatment for 1 hour at 37°C, cells were incubated with 
propidium iodide (0.4 mg/mL; Invitrogen), and analyzed immediately.  Media-treated 
splenocytes served as controls to set gates for no proliferation (CFSE) and cell cycle stages (PI). 
To measure glucose uptake, stimulated cells were incubated with 100 µM 2-(N-(7-
Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose (2-NBDG; Molecular Probes), a 
fluorescent glucose analog (Life Technologies), for 10 minutes at 37°C prior to harvest [136].  
Uptake was quenched with PBS.  Cells were stained for surface CD4 expression and analyzed by 
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flow cytometry live.  Fluorescence was measured using a FACS Calibur or LSR II flow 
cytometer (BD Biosciences).  All data were analyzed using FlowJo software (v10.1) and samples 
were gated on CD4+ cells.   
 
3.3.8 Cytokine and lactate measurements 
Supernatants from cell cultures were analyzed for IFNγ and IL-2 by ELISA according to 
manufacturer’s instructions (BD Biosciences).  ELISAs were read on a SpectraMax M2 
microplate reader (Molecular Devices), and data were analyzed using SoftMax Pro version 5.4.2 
software (Molecular Devices).  Lactate, a byproduct of aerobic glycolysis, was measured in 
culture supernatants using the Accutrend Plus meter and lactate strips (Roche).  Samples with 
high concentrations of lactate were diluted 1:2 in dI H20 in order to obtain a reading within the 
meter’s range. 
 
3.3.9 Quantitative real-time PCR (qRT-PCR) 
At 24 hours post-stimulation in vitro, cells were harvested and washed extensively with PBS.  
5.0 x 106 cells were lysed using RLT buffer (Qiagen) and 25 gauge needles with 1 mL syringes.  
mRNA was isolated using the RNeasy kit (Qiagen) and concentration was determined using a 
NanoDrop 2000c spectrophotometer (Thermo Scientific).  cDNA was synthesized from 0.5 µg 
mRNA using the RT2 First Strand Kit (Qiagen).  Gene expression was quantified by qRT-PCR 
using the iQ SYBR Green Supermix (BIORAD) and iCycler (BIORAD).  Murine glycolytic 
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primer pair sequences were taken from Wang et al. [103].  Ifnγ primers were FWD 5’-
AGGCCATCAGCAACAACATAAGCG-3’ and REV 5’- 
TGGGTTGTTGACCTCAAACTTGGC-3’.  Cycling parameters were as follows:  5 min at 
95°C, 30 s at 95°C, 30 s at 60°C, 30 s at 72°C (40 cycles of steps 2-4), 1 min at 95°C, and then 
samples were held at 4°C.  Delta delta Ct values were normalized to expression of the control 
gene rplo (FWD 5’-GGCGACCTGGAAGTCCAACT-3’; REV 5’-
CCATCAGCACCACAGCCTTC-3’) [342], in order to calculate relative expression.  Mimotope 
and M + MnP expression values were normalized to those of unstimulated, media controls. 
 
3.3.10 Adoptive transfer model of T1D 
Spleens from NOD.BDC.2.5.TCR.Tg animals were homogenized and processed as described 
above.  Whole splenocytes were labeled with Cell Proliferation Violet (BD Biosciences) 
according to manufacturer’s instructions, and 1.0x107 splenocytes were adoptively transferred 
into NOD.scid recipients i.v.  One cohort of recipients was treated with 10 mg/kg MnP i.p. every 
day or s.c. every other day, starting the day prior to transfer.  Serum was collected on days -1, 3, 
7, 11, and 15 post-transfer to measure sLAG-3 by ELISA as an indication of T cell activation, as 
previously described [168].  T1D incidence was monitored by blood glucose post-transfer, and 
two consecutive readings of > 350 mg/dL was deemed diabetic.  At indicated time points, 
animals were sacrificed and peripheral blood and spleens were taken for downstream analysis by 
flow cytometry.  1.0x106 splenocytes were stained with surface antibodies for CD4, CD25, and 
LAG-3 following Fc receptor blockade with anti-CD16/CD32 (all from BD Bioscience). For 
intracellular pS6 staining of peripheral blood, red blood cells were lysed and then lymphocytes 
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were surface stained.  Following fixation and permeabilization using Cytofix/Cytoperm (BD 
Bioscience), cells were then stained using the pS6 Alexa 488 antibody (Cell Signaling). Cells 
were then analyzed by flow cytometry using a BD LSRII (BD Bioscience) and FlowJo software 
(v10.1). 
 
3.3.11 Statistical analysis 
Data are given as mean values ± SEM, with n indicating the number of independent experiments 
or animals, unless otherwise indicated.  Student’s t-test and Two-way ANOVA with Bonferroni 
post-hoc analysis were used where appropriate. Kaplan-Meier analysis was used to measure 
significance of diabetes incidence. A p-value of p < 0.05 was considered significant for all 
statistical analyses. 
3.4 RESULTS 
3.4.1 Treatment of T cells with MnP effectively scavenges NADPH oxidase and 
mitochondrial-derived ROS and without toxicity 
T cells generate ROS via two sources – a phagocyte-like NADPH oxidase [213, 225] and 
mitochondrial electron leak [244].  As blockade of each of these sources have differential effects 
on T cell activation and differentiation, we wanted to further delineate if MnP treatment 
successfully scavenges ROS from both sources.  To do so, the fluorescent indicators 
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dyhidoethidium (DHE) and MitoSOX were utilized as both dyes only fluoresce upon 
modification by superoxide.  DHE measures total superoxide generation, whereas MitoSOX 
specifically measures that from the mitochondria.  Following pre-treatment with either media 
alone or media with MnP, splenocytes were stimulated with PMA and ionomycin which are 
known to induce ROS production by T cells [201, 213, 244].  As anticipated, MnP treatment 
successfully reduced total superoxide generation as measured by DHE (Figure 22A).  
Additionally, mitochondrial-derived superoxide generation was also diminished by MnP 
treatment (Figure 22B), indicating that MnP is capable of entering the mitochondria.  Together 
these data reveal that MnP effectively dissipates ROS from both NADPH oxidase and the 
mitochondria, resulting in reduced total cellular ROS production. 
 Viability of splenocyte cultures was also assessed to confirm that effects on T cell 
activation and metabolism were not simply due to MnP toxicity.  7AAD staining results 
demonstrated no significant difference in viability of either whole splenocytes (Figure 22C) or 
CD4+ T cells (Figure 22D), supporting that the subsequent impact of MnP treatment on T cell 
metabolic reprogramming is not simply due to agent-associated toxicity. 
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Figure 22. MnP treatment effectively scavenges NADPH oxidase and mitochondrial derived superoxide, while 
demonstrating no toxicity. 
NOD splenocytes were pre-treated with or without MnP and then loaded with either A. Dihydroethidium (DHE) or 
B. MitoSOX red.  Splenocytes were stimulated with PMA and ionomycin and read for fluorescence by flow 
cytometry at the indicated time points.  Data are displayed as delta mean fluorescence intensity (∆ MFI) ± SEM 
calculated as MFIstimulated – MFIunstimulated.  C-D. BDC2.5.TCR.Tg splenocyte cultures were stained for 7AAD and 
CD4 to assess viability of cultures due to MnP treatment.  Data are displayed as percent 7AAD- of C. whole 
splenocytes and D. CD4+ T cells.  Significance was determined by Two-way ANOVA with Bonferroni post-hoc 
analysis of a combined n = 3-5 mice (****=p<0.0001; ***=p<0.001; **=p<0.01; *p<0.05). 
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3.4.2 Scavenging of ROS during activation halts CD4+ T cells at the G0/G1 checkpoint and 
inhibits clonal expansion 
Acute doses of ROS are required for cell cycle progression and proliferation of CD4+ T cells 
[209, 295]. Therefore, we wanted to examine if scavenging of ROS via MnP treatment inhibited 
this process during activation. Here, we utilized the NOD.BDC.2.5.TCR.Tg (BDC.2.5) mouse 
model, in which the CD4+ T cells of this animal have been shown to demonstrate diabetogenic 
potential [7]. CD4+ T cells from BDC.2.5 animals stimulated with their specific antigen 
mimotope (M), demonstrated high proliferative capacity as demonstrated by CFSE dilution 
(Figure 23A).  ROS inhibition via MnP treatment during antigen-dependent stimulation resulted 
in CD4+ T cells undergoing fewer rounds of proliferation at both 48 and 72 hrs post-stimulation 
as compared to stimulation alone (Figure 23A).  CD4+ T cells treated with MnP did show low 
levels of proliferation, which was not surprising as MnP does not fully block all ROS production 
(Figure 22A and B). 
Since overall proliferation was reduced due to MnP treatment, we wanted to examine if 
CD4+ T cells were being arrested at a specific cell cycle checkpoint.  Consequently, propidium 
iodide staining was used to examine the distribution of CD4+ T cells in the various phases of the 
cell cycle – G0/G1, S, and G2/M.  By 48 hours post-stimulation, significantly fewer CD4+ T cells 
had progressed to the later stages of the cell cycle (S phase and G2/M phase) following MnP 
treatment, as compared to stimulated controls (Figure 23B-C; p<0.05).  These results correlated 
with increased expression of the cell cycle inhibitor p27 Kip1 (Figure 23D), which is responsible 
for restricting progression from G1 to S phase [378].  Additionally, protein analysis demonstrated 
reduced expression of Cyclin D3, a promoter of S phase transition, due to MnP treatment, again 
indicating limited cell cycle progression (Figure 23D).  p27 Kip1 is also a potent Cyclin D3 
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inhibitor [379], and therefore, its maintained expression results in cell cycle arrest.  Together, 
these results indicate that dissipating ROS during activation halts CD4+ T cells at the G1/S 
checkpoint in the cell cycle via maintaining p27 Kip1 expression. 
  

































Figure 23. Redox modulation during activation inhibits cell cycle progression of CD4+ T cells. 
NOD.BDC.2.5.TCR.Tg splenocytes were plated in complete splenocyte media and stimulated with 0.05 µM 
mimotope with or without 68 µM MnP (M + MnP) for 48-72 hours.  A.  Prior to stimulation cells were loaded with 
1 µM CFSE.  Cells were stained with CD4 following harvest and analyzed by flow cytometry for CFSE dilution, 
indicating proliferation.  Unstimulated cells (grey shaded curve) served as negative controls to set proliferation 
gates.  CFSE tracings are representative of n > 3 independent experiments.  B.  Cells were fixed, permeabilized, and 
stained with propidium iodide and CD4-FITC.  Cells were analyzed by flow cytometry to determine cell cycle 
status.  CD4+ T cells were gated on and cell cycle phases were set based upon unstimulated controls (left panel). C.  
Percentages of n > 3 experiments were combined and graphed as mean ± SEM (*=p<0.05).  D. 48 hrs. post-
stimulation, cells were harvested and analyzed by Western blot for p27 Kip1 and Cyclin D3 expression.  β actin 
expression served as the loading control.  
 
  111 
3.4.3 Transition to aerobic glycolysis during CD4+ T cell activation is dependent upon 
cellular redox status 
CD4+ T cells undergo massive metabolic reprogramming during the transition from naïve to 
effector states [103, 380], and in order to support this metabolic reprogramming, CD4+ T cells 
must upregulate various glycolytic enzymes, transcriptional regulators, and glucose transporters 
[103].  Impeding this process results in reduced clonal expansion [46], effector function [358], 
and overall T cell responses in disease models [49].  Proliferation and metabolism are two tightly 
coupled cellular processes, and inhibition of glycolysis has been shown to result in diminished 
proliferation [362].  Therefore, we hypothesized that as ROS scavenging diminished CD4+ T cell 
proliferation (Figure 23), it may be doing so by modulating metabolic reprogramming.     
The transcription factor Myc is critical for promoting aerobic glycolysis in both CD4+ T 
cells and tumors alike, by initiating expression of various glycolytic enzymes and glucose 
transporters [103, 363], along with driving cell cycle progression [363].  Protein and quantitative 
RT-PCR analysis of in vitro stimulated BDC2.5.TCR.Tg splenocytes confirmed increased Myc 
expression at 24 and 48 hours post-stimulation (Figure 24A,C).  In contrast, MnP treatment 
resulted in contracted Myc upregulation at both time points (Figure 24A,C).  These results 
correlated with reduced mRNA expression of several Myc-dependent genes necessary for 
aerobic glycolysis including glut1, hexokinase 2 (HK2), lactate dehydrogenase A (LDH A), and 
pyruvate kinase M2 (PKM2) (Figure 24B,C; p<0.05). 
Following gene expression analysis, we sought to investigate protein expression of two 
key Myc-dependent targets – Glut1, the glucose transporter expressed by activated T cells that 
has the greatest impact on differentiation [357, 381]; and, PFKFB3, a rate limiting enzyme that 
aids in committing glucose to being metabolized via glycolysis [382].  Also, modulation of 
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activity and expression of PFKFB3 in autoreactive T cells has been shown to ameliorate disease, 
suggesting PFKFB3 as a potential therapeutic target for autoimmunity [382, 383].  As 
anticipated, protein expression of Glut1 was reduced in MnP-treated splenocytes, further 
corroborating qRT-PCR results (Figure 24C).  However, while qRT-PCR results did not show 
differences in mRNA expression of the enzyme PFKFB3 (Figure 24D), protein analysis did 
show reduced upregulation due to MnP scavenging ROS (Figure 24D).  These results underscore 
the importance ROS play in enabling the transcriptional alterations necessary for aerobic 
glycolysis.    
As glucose is the primary substrate for aerobic glycolysis, and our data indicated that MnP 
treatment inhibited Glut1 expression, we wanted to measure the effect of MnP treatment on 
glucose uptake.  To do so, splenocyte cultures were incubated with the fluorescent glucose 
analog 2-NBDG, and uptake was measured by flow cytometry.  As with diminished Glut1 
expression, MnP treatment resulted in reduced glucose uptake by CD4+ T cells (Figure 24E).  
These results correlated with reduced lactate production, the byproduct of aerobic glycolysis, as 
measured in culture supernatants, further indicating a significant reduction in the utilization of 
aerobic glycolysis due to redox modulation (Figure 24F; p<0.01).  Overall, these data reveal that 
alterations in CD4+ T cell redox status limits upregulation and utilization of the glycolytic 
pathway necessary for driving effector differentiation and clonal expansion. 
  





































Figure 24. Transition to aerobic glycolysis during CD4+ T cell activation is dependent upon cellular redox 
status. 
A.  Protein lysates were probed for Myc expression.   β actin expression served as the loading control. B.  Glycolytic 
pathway with assayed Myc-dependent genes indicated in red.  C.  24 hours post-stimulation, mRNA expression of 
various glycolysis-associated genes was assessed by qRT-PCR.  Relative values were normalized to unstimulated, 
naïve controls (Media).  Data displayed are means of n = 5-7 independent experiments ± SEM. D. Western blot 
analysis of specific Myc targets, PFKFB3 and Glut1.  E.  48 hours post-stimulation, cells were treated with 100 µM 
2-NBDG and stained for CD4 following incubation.  Glucose uptake was measured as 2-NBDG fluorescence of the 
CD4+ population.  Histograms are representative of n > 3 experiments.  F.  Lactate was measured in culture 
supernatants using the Accutrend Plus meter (Roche).  Data are graphed as means of n > 3 experiments ± SEM.  
Statistical significance between mimotope and M + MnP groups was calculated using a Student’s t test (*=p<0.05, 
**=p<0.01). 
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3.4.4 mTOR signaling is reduced upon treatment with MnP 
The mammalian target of rapamycin (mTOR) pathway has been shown to be pivotal in driving 
metabolic changes during T cell activation and regulating CD4+ T cell lineage commitment [384, 
385]. Studies examining the effects of rapamycin on T cell metabolism have indicated that 
inhibition of mTOR activation and signaling during T cell activation resulted in diminished 
proliferation, effector function, and glycolytic capacity [365].  Given the fact that MnP treatment 
inhibited cell cycle progression (Figure 23) and aerobic glycolysis (Figure 24), and that the 
mTOR pathway is critical in mediating both of these processes, we sought to measure mTOR 
activation and its downstream signaling. 
Protein analysis of in vitro stimulations indicated that MnP treatment during mimotope 
stimulation resulted in reduced total mTOR expression and also activation, as measured by 
phosphorylation at Ser2448 at 48 and 72 hours post-stimulation (Figure 25A).  We also 
examined phosphorylation of mTOR’s downstream target 4E-BP1, a translational repressor that 
is inhibited upon hyperphosphorylation [364].  Reduced phosphorylation of 4E-BP1 (Thr70) was 
exhibited in MnP treated CD4+ T cells, as compared to stimulated controls (Figure 25A), 
indicating reduced mTOR signaling.  
In addition to driving activation, mTOR signaling is also necessary for mediating the 
growth phase of mammalian cells in preparation for expansion [386] and driving effector 
differentiation in T cells [364]. As anticipated, with reduced mTOR signaling, MnP-treated 
CD4+ T cells demonstrated reduced growth at 48 hours as measured by forward scatter (Figure 
25B), and reduced IFNγ secretion (Figure 25C; p<0.05).  Additionally, we assessed IFNγ mRNA 
expression by splenocytes 24 hours following stimulation.  qRT-PCR results indicated that MnP 
treatment during stimulation hindered upregulation of IFNγ mRNA as compared to mimotope 
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stimulation alone (Figure 25D; p<0.05), suggesting that the reduced secreted levels due to ROS 
scavenging was not simply due to reduced proliferation and the presence of fewer T cells.  
Overall, these results indicate that ROS signaling is required for amplifying mTOR signaling 
upon activation, which then enables optimal T cell proliferation (Figures 23) and glycolysis 
(Figures 24).   
We also examined Interleukin-2 (IL-2) levels in our in vitro cultures, as IL-2 is essential 
for aiding T cell clonal expansion.  Interestingly, we saw no defect in IL-2 production due to 
MnP treatment as compared to stimulation alone at all time points examined (Figure 25E).  
Additionally, there was no difference in expression of the high-affinity IL-2 receptor subunit, 
CD25 (Figure 25F).  These results suggest that while redox modulation has no effect on the 
production of IL-2 or receptor expression, it does alter downstream signaling as mTOR signaling 
is, in part, IL-2 driven. 
  









































Figure 25. mTOR signaling is inhibited upon MnP treatment. 
A. Western blot analysis for phosphorylated mTOR (Ser4998; active), total mTOR, and the downstream mTOR 
target, phosphorylated 4E-BP1 (Thr70).  β actin expression served as the loading control.  B.  Forward scatter (FSC) 
of CD4+ T cells was measured by flow cytometry as an indication of cell blasting.  Histogram is representative of n 
> 3 experiments.  Supernatants from in vitro stimulations were analyzed for C. IFNγ and E. IL-2 production by 
ELISA.  D. qRT-PCR to measure IFNγ expression at 24 hrs. post-stimulation.  F. Frequency of CD4+ T cells 
expressing CD25 following activation.  Data displayed are combined means ± SEM of n > 5 experiments.  Statistical 
significance was calculated using a two-way ANOVA with Bonferroni post-hoc analysis. (*=p<0.05).  Media alone 
treated splenocytes served as negative controls.    
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3.4.5 Inhibition of T cell generated ROS reduces proliferation, growth, and glucose 
uptake  
Third signal ROS are necessary for driving T cell activation, and our data here indicate they are 
also critical for facilitating metabolic reprogramming (Figure 24-25).  Previous work has 
revealed that both APCs and T cells express functional NOX enzymes that are activated during 
MHC-TCR engagement, resulting in ROS production from both the APC and T cell [201, 213, 
226].  Therefore, we sought to further delineate if T cell-derived ROS were alone sufficient for 
mediating the transition to aerobic glycolysis during activation, and if MnP treatment would 
inhibit this process.   
To do so, CD4+ T cells were isolated from whole splenocytes and stimulated in vitro with 
plate-bound αCD3/αCD28, with or without MnP.  Flow cytometric analysis of stimulated T cells 
indicated that ROS inhibition by MnP resulted in reduced proliferation at both 48 and 72 hours 
post-stimulation as compared to activated T cells not treated with MnP (Figure 26A).  ROS 
scavenging also resulted in reduced cell growth during activation as measured by forward scatter 
(Figure 26B) and glucose uptake at 72 hours post-stimulation (Figure 26C-D; p<0.01).  These 
results are in accordance with data presented in Figures 23-25, and further elucidate that the role 













































Figure 26. T cell-derived ROS are sufficient for enabling aerobic glycolysis during activation. 
Isolated CD4+ T cells were stimulated with plate-bound αCD3/αCD28 with or without MnP treatment.  A.  
Proliferation as measured by dilution of Cell Trace Violet.  B.  Forward scatter as measure of size following 
activation.  C-D.  Glucose (2-NBDG) uptake by CD4+ T cells measured by flow cytometry and normalized to 
unstimulated control T cells.  **=p<0.01; ****=p<0.0001.  Data are combined or representative of n = 5 
independent experiments.   
  119 
3.4.6 MnP treatment enhances activation of AMPK 
AMPK, or adenosine monophosphate activated protein kinase, is a nutrient sensor shown to be 
responsible for driving oxidative metabolism due to ATP depletion, and it becomes active 
following phosphorylation of its catalytic α subunit [203, 367, 387].  The antioxidant resveratrol 
has been shown to activate AMPK [366], and AMPK is an established negative regulator of the 
Warburg effect (aerobic glycolysis) [368] and mTOR signaling [203, 369]. Since our data 
indicated that MnP treatment inhibits mTOR-driven aerobic glycolysis in CD4+ T cells, and MnP 
is a potent antioxidant [324, 376], we hypothesized that MnP treatment would result in AMPK 
activation, thereby inhibiting mTOR signaling and aerobic glycolysis.   
AMPK is highly activated in naïve T cells, and protein analysis demonstrated that the 
levels of AMPK phosphorylation (Thr172) due to MnP treatment were comparable to those of 
media-treated, naïve cells, as indicated by a relative expression value of 1 (Figure 27).  
Mimotope stimulation alone resulted in reduced AMPK phosphorylation at 48 hours as 
compared to both media and MnP-treated splenocytes (Figure 27).  These results reveal that MnP 
treatment may not enhance AMPK activation, but rather maintain active levels even in the 
presence of antigenic stimulation, thus impeding mTOR signaling and aerobic glycolysis. 
  









Figure 27. Alteration in redox status of CD4+ T cells maintains AMPK activation. 
Protein lysates were probed with antibodies for phosphorylated AMPK-1α (Thr172; activated), total AMPK, and β 




3.4.7 Inhibition of aerobic glycolysis due to redox modulation limits the diabetogenic 
potential of autoreactive CD4+ T cells 
In order to test if inhibiting progression to aerobic glycolysis in CD4+ T cells delayed diabetes 
incidence, an adoptive transfer model was used (Figure 28A).  Here, BDC.2.5.TCR.Tg 
splenocytes were isolated and transferred i.v. into non-diabetic NOD.scid recipients.  A cohort of 
the recipient animals was treated with 10 mg/kg MnP starting the day prior to adoptive transfer 
as described in the methods.  80% of untreated controls exhibited fulminant diabetes by 12 days 
post-transfer (Figure 28B); however, MnP treatment inhibited diabetes progression, with only 
20% of treated animals becoming diabetic throughout the duration of the experiment (Figure 
28B; p=0.0233).   
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We and others have reported that increased serum levels of the inhibitory receptor 
Lymphocyte Activation Gene-3 (LAG-3) due to its redox-dependent cleavage from the surface 
of T cells, serves as a viable marker of T cell activation [169, 170] and conceivable predictor of 
T1D [168].  Therefore, we measured soluble LAG-3 (sLAG-3) in the serum of recipient animals 
at various time points post-transfer, as a means of measuring T cell activation.  At day 7 post-
transfer, while all animals were euglycemic, control animals presented with elevated serum 
levels of sLAG-3 as compared to those treated with MnP (Figure 28C).  Those controls went on 
to become diabetic by day 11 post-transfer, while animals treated with MnP did not (p<0.01).  
Together, these data demonstrate that sLAG-3 serum levels, as a measure of T cell activation, 
predicts diabetes onset, and MnP treatment controls this redox-dependent process.   
Splenocytes from recipient animals were analyzed by flow cytometry to assess T cell 
activation in vivo.  Two markers of activation were measured: CD25, the IL-2 high affinity 
receptor, and LAG-3 (Figure 28D), as both markers are more highly expressed on the surface of 
activated CD4+ T cells than on naïve T cells [139, 347].  CD4+ T cells from diabetic controls 
displayed increased frequency of CD25+LAG-3+ double positive T cells, indicative of an 
activated phenotype, in comparison to CD4+ T cells from MnP treated non-diabetic animals 
(Figure 28D; p = 0.0761). 
 As in vitro results indicated reduced mTOR signaling (Figure 26), we also wanted to 
confirm these results in vivo.  Peripheral blood samples were taken at day 4 post-adoptive 
transfer and levels of phosphorylated S6 ribosomal protein (S6), an mTOR target, were measured 
by flow cytometry.  Results indicated two populations of CD4+ T cells with respect to pS6 
expression, CD4+pS6hi T cells and CD4+pS6lo T cells (Figure 28E).  CD4+ T cells from MnP 
treated animals exhibited a lower frequency of pS6hi cells (Figure 28E-F), as compared to T cells 
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from control animals, indicating reduced T cell activation due to MnP treatment.  Moreover, pS6 
expression (as measured by mean fluorescence intensity) was increased in CD4+pS6hi T cells 
from control animals compared to the MnP-treated cohort (Figure 28G).  These results suggest 
that those T cells that do receive some activation signal despite the presence of MnP, are still 
unable to induce mTOR signaling to the extent of stimulated controls.  Lastly, studies from 
Pollizzi et al. demonstrated that T cells with high levels of mTOR signaling during activation, 
were larger than those with lower mTOR activation [126].  In accordance with these and other 
studies, CD4+pS6hi T cells were larger than the CD4+pS6lo T cells, regardless of treatment 
(Figure 28H). Yet, as with higher mTOR signaling induction in control T cells (Figure 28G), 
pS6hi T cells from these animals were also larger than those treated with MnP (Figure 28H), 
supporting their finding that T cell size is directly related to mTOR activity and activation [124].  
These results demonstrate that MnP treatment in vivo alters mTOR signaling during T cell 
activation, resulting in reduced CD4+ T cell diabetogenicity.  






































Figure 28. Reducing glycolytic capacity by redox modulation inhibits diabetogenic potential of CD4+ T cells. 
A.  Schematic of adoptive transfer model of T1D.  B.  Survival curve of diabetes free animals following adoptive 
transfer.  Animals were deemed diabetic following 2 consecutive blood glucose readings of >350 mg/dL.  Statistical 
significance of disease progression was calculated using a Kaplan-Meier test (*=p<0.05).  C.  T cell activation and 
prediction of diabetes was measured by serum levels of sLAG-3 by ELISA.  Statistical significance was calculated 
using a Two-way ANOVA with Bonferroni post-hoc analysis. (**=p<0.01).   D. Normalized percent of LAG-
3+CD25+CD4+ T cells from spleens of control diabetic and MnP-treated non-diabetic animals (n = 6-8 animals per 
group; p = 0.0761).  E. Mean fluorescence intensity of pS6 in peripheral blood CD4+ T cells from animals at day 4 
post-transfer.  F. Representative histograms of S6 phosphorylation from peripheral blood CD4+ T cells at day 4 post-
transfer from control and MnP treated animals. G-H. Quantification of frequency of pS6hi and pS6lo CD4+ T cells.  I. 
Forward scatter analysis of pS6lo and pS6hi CD4+ T cells.   
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3.5 DISCUSSION 
Work from our laboratory and others has demonstrated that acute doses of ROS are required for 
mediating T cell activation, and that ROS inhibition results in dampened T cell responses [168, 
202, 225, 244, 304].  Treatment with a manganese metalloporphyrn (MnP) successfully 
scavenges a significant amount of the ROS produced, with no toxicity to the T cells themselves 
(Figure 23).  Cell cycle entry and proliferation have been shown to be highly dependent upon 
ROS signaling, as many cyclin-dependent kinases that mediate cell cycle progression, and cell 
cycle inhibitors are known to be redox sensitive [295].  Indeed, our results indicated that 
dissipating ROS by MnP resulted in reduced cell cycle entry via maintenance of the cell cycle 
inhibitor p27 Kip1 (Figure 23).  Interestingly, T cell proliferation and effector function were not 
completed ablated upon MnP treatment, potentially since MnP treatment did not completely 
dissipate all superoxide generated upon T cell activation (Figure 22A-B).  Additionally, 
completely depleting the cell of all ROS would result in toxicity.  These results highlight that 
fine-tuning of ROS signaling has dramatic effects on T cell outcome. 
In order to transition to an effector after activation, naïve CD4+ T cells must undergo 
massive reprogramming at the metabolic level, transitioning from oxidative phosphorylation to 
aerobic glycolysis [49, 50, 362].  Aerobic glycolysis, or the Warburg effect, is required for 
supporting optimal T cell clonal expansion and macromolecule synthesis, yet how ROS affect 
metabolic reprogramming during T cell activation remains poorly understood.  Here, our data 
indicate that ROS are necessary for driving optimal mTOR signaling (Figure 26A) and 
upregulation of the transcription factor Myc (Figure 25A), two key players that have roles in 
coordinating both aerobic glycolysis and cell cycle entry [104, 363, 364].  It has been reported 
that T cell effector function is tightly regulated by both aerobic glycolysis and cell cycle.  In fact, 
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proliferation and IFNγ production have a direct relationship – as rounds of proliferation increase 
so does IFNγ production [305]  Our results reiterate these findings in that redox modulation 
inhibits aerobic glycolysis (Figure 24) and proliferation (Figure 24), concomitant with IFNγ 
secretion (Figure 26C).  Also, these findings suggest that redox reactions in fact supersede these 
pathways. 
A well described characteristic of T cells is that they divide asymmetrically, generating 
two distinctly different daughter cells.  These daughter cells exhibit differential mTOR 
activation, cellular metabolism, and eventual differentiation [123, 126, 127].  Specifically, the 
larger, mTORhi, glycolytic daughters demonstrate a more T effector phenotype, whereas the 
smaller, mTORlo, oxidative daughters are more memory-like [124, 126, 127].  Interestingly, 
redox modulation skewed T cells towards a higher percentage of mTORlo T cells as compared to 
untreated controls (Figure 28E-H), which may suggest a role for redox in asymmetric division.  
It is also plausible that scavenging of ROS is simply inhibiting activation and the pS6lo T cells 
are those that remain naïve.  Also in this report, Pollizzi et al. indicated that there was no 
difference in CD25 surface expression between mTORhi and mTORlo T cells [124].   Even with 
CD25 expression and the presence of IL-2, mTORlo T cells failed to proliferate as robustly [386], 
which is in accordance with the in vitro results demonstrated (Figure 25D-E), suggesting some 
additional regulatory mechanism(s) at play.  It seems plausible that ROS could be a contributing 
factor in mediating T cell asymmetry; however, further studies would be necessary. 
As mentioned, one of the downstream targets of mTOR is 4E-BP1, a translational 
repressor [386].  For translation to ensue, hyperphosphorylation of 4E-BP1 by mTOR is critical 
for inhibition of the repressor.  Since our data indicate a decrease in phosphorylation or 
inhibition of 4E-BP1, it is likely that maintenance of the repressor contributed to the reduced 
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protein expression of Glut1 and PFKFB3 (Figure 24E).  This, coupled with reduced Myc 
expression, may synergistically impede metabolic reprogramming.  With regards to cell cycle 
progression, inhibition of 4E-BP1 by mTOR is required for promoting expression of Cyclin D3 
[365].  Additionally, mTOR signaling has been shown to lead to increased p27 Kip1 degradation 
as a means of supporting cell cycle progression [365].  Therefore, MnP-mediated decreased 4E-
BP1 hyperphosphorylation likely contributed to decreased Cyclin D3 expression and decreased 
p27 Kip1 degradation (Figure 23D), promoting cell cycle arrest.      
 CD4+ T cells are a primary mediator of immunopathology in T1D; therefore, we wanted 
to determine if inhibiting metabolic reprogramming by MnP treatment reduced their 
diabetogenic potential.  As anticipated, modulating the CD4+ T cell glycolytic rate via MnP 
delayed T1D onset in an adoptive transfer model (Figure 28B).  T1D is known to be highly 
driven by free radicals.  Not only does oxidative stress result in islet beta cell death, but it also 
serves to activate and mobilize inflammatory macrophages and T cells, driving even more 
immunopathology.  Therefore, further outlining the mechanisms in which these molecules 
influence immune cells is vital.  More recent studies in other autoimmune diseases like systemic 
lupus and rheumatoid arthritis have helped to delineate potential for metabolic-based therapies in 
ameliorating disease [188, 189, 383], further supporting the need to more fully understand 
mechanisms governing immune cell metabolism.  It is worth noting that in rheumatoid arthritis, 
pathogenic T cells were shown to produce increased levels of ROS that resulted in glycolysis 
inhibition and increased apoptosis [388].  Consequently, ROS may play different roles depending 
on the disease context, making it even more imperative to further understand their influence.   
In summary, we have demonstrated that ROS inhibition by a manganese 
metalloporphyrin during diabetogenic CD4+ T cell activation is capable of impeding the 
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metabolic transition from oxidative phosphorylation to aerobic glycolysis necessary for optimal 
T cell responses.  We propose a model in which ROS and cellular redox balance is critical for 
amplification of the mTOR/Myc pathway, and thus aerobic glycolysis (Figure 29).  These 
findings present potential implications in tempering T cell responses in autoimmunity, and also 


























Figure 29. Mechanism for the effect of ROS inhibition on CD4+ T cells during activation-induced metabolic 
reprogramming. 
Upon T cell receptor – MHC interaction, ROS are generated by a functional NOX expressed by T cells.  These ROS 
serve as signaling molecules to help propagate mTOR signaling resulting in Myc upregulation and progression to 
aerobic glycolysis.  Treatment with the ROS-scavenging and potent antioxidant results in inhibition of ROS and 
maintains potent AMPK activation; thereby, inhibiting mTOR via a two-pronged approach, stabilizing OXPHOS, 
and limiting T cell proliferation 
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4.0  FUTURE DIRECTIONS 
4.1 LAG-3 AND T CELL METABOLISM 
4.1.1 Metabolite oxidation and mitochondrial phenotype  
While the data presented in chapter 2 demonstrate that LAG-3 negatively regulates 
mitochondrial biogenesis and metabolism, one question that remains is which metabolite is 
responsible for supporting this function.  Fatty acids, glucose and glutamine can all be oxidized 
by the mitochondria, making them each a potential candidate in our model.  Seahorse 
experiments were performed using specific pathway inhibitors during mitochondrial stress tests 
to see which resulted in reduced basal OCR and/or SRC.  However, they proved inconclusive.  
These experiments are still ongoing and our working hypothesis is that fatty acids will be the 
critical metabolite.  This hypothesis is based upon the fact that our studies concluded LAG-3-/- T 
cells are metabolically similar to memory T cells, and fatty acid metabolism is necessary for 
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4.1.2 T cell metabolism in Type 1 Diabetes 
As discussed in Chapter 1, there is mounting evidence that autoreactive T cells are metabolically 
different from other T cells.  These differences include increased mitochondrial membrane 
potential and mutations, enhanced glycolysis and OXPHOS, and a greater dependence on 
glutamine metabolism.  The majority of the work investigating metabolic differences have been 
done in diseases like MS, Lupus, and RA, with very little investigating T cell metabolism in 
T1D.  With the knowledge we have gained from studies in these other autoimmune diseases, its 
highly plausible that there are metabolic abnormalities in diabetogenic T cells.  Future 
experiments comparing glycolytic and oxidative capacities during naïve and effector states of 
diabetogenic (NOD) and non-autoimmune (B6) T cells may reveal differences, which in turn 
could suggest the use of metabolic-based therapies in the disease, as these types of therapies have 
proven efficacious in other autoimmune diseases.  For example, in the animal model of Lupus, 
inhibition of utilization of the chemicals 2-deoxyglucose and metformin reversed metabolic 
dysfunction, thus ameliorating disease [188].  Additionally, targeting glutamine metabolism in 
EAE reduced Th17 differentiation and pathogenicity [111].  There is some evidence that effector 
T cells in T1D are refractory to T regulatory cell mediated suppression [323].  It is highly 
plausible that underlying metabolic advantages protect effector T cells from being suppressed, 
and weakening this advantage via targeted therapy could lower this metabolic threshold, thereby 
leaving effector T cells vulnerable to T regulatory cell-mediated suppression.   
As mentioned previously, LAG-3 knockout in the NOD model leads to accelerated T1D 
progression, due to heightened CD4+ T effector cell responses [155, 158].  Our data would 
suggest that LAG-3 deficiency in these T cells results in enhanced bioenergetics thus driving 
greater activation potential, resulting in disease acceleration.  These data provide the basis for 
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future studies examining what effect this metabolic phenotype has in the context of 
autoimmunity.  Based on the data presented in chapter 2, we would hypothesize that increased 
mitochondrial mass and metabolism in naïve T cells, coupled with an autoreactive TCR, could 
make for an even more pathogenic T cell.  Future studies could examine if metabolic differences 
exist during activation by comparing mitochondrial characteristics and metabolic profile of 
NOD.LAG-3 sufficient and deficient T cells during T1D induction.   
While these proposed studies would further our understanding of metabolic differences 
during activation, they would not elucidate what advantage alterations during T cell homeostasis 
provide for activation.  The difficulty lies in that NOD T cells exhibit characteristics of activation 
even in young animals, since they develop in the presence of their antigen, the β cell.  Currently, 
we are working on experiments utilizing a novel NOD TCR transgenic animal, the NOD.BDC-
6.6.9 strain.  Here, all CD4+ T cells recognize an autoantigen that is unique to NOD islets [390].  
The region of the genome encoding this peptide was mapped and replaced with a Balb/c 
sequence that does not encode the antigenic peptide [390].  Therefore, these CD4+ T cells, that 
are capable of inducing T1D following adoptive transfer into NOD.scid animals, are educated 
and develop in an environment devoid of their cognate antigen.  Thus, they are autoreactive, yet 
entirely naïve.  We plan to recapitulate adoptive transfer experiments into NOD.scid animals 
with and without LAG-3 antibody blockade (as LAG-3 knockout animals on this background do 
not exist) to assess metabolic differences as described in chapter 2.  These experiments would 
expand our understanding of the role of LAG-3 in autoreactive T cell homeostatic expansion and 
metabolism and its relevance in T1D.   
One caveat is that we will need to deplete the endogenous β cells in the NOD.scid 
animals via streptozotocin treatment as to eliminate the source of antigen, and therefore, blood 
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glucose in these animals will need to be maintained by insulin pellets.  If similar differences do 
arise due to LAG-3 blockade, we could then transplant NOD islets back into the recipient 
animals to assess if the differences in T metabolism augment activation and disease progression.     
Translating our studies into humans would also be a future direction for this project.  As 
with studies performed using samples from SLE patients, it would be interesting to receive 
peripheral blood samples from patients and first degree relatives to investigate the metabolic 
profile of T cells.  Taking this one step further, DNA sequencing could be used to identify SNPs 
in the LAG-3 gene or any others that may have implications on metabolism.  We currently have 
a collaboration with Dr. Eddie James, PhD., who has isolated autoreactive T cell clones from 
Type 1 diabetics.  Preliminary DNA sequencing studies using these T cells and those from health 
controls could be performed to then provide a basis for further investigation. 
 
4.1.3 LAG-3 expression and memory T cell formation 
One mechanism of memory T cell formation is by the contraction of activated effectors 
following resolution of the immune attack.  With this contraction, glycolytic effectors must 
transition back to relying on OXPHOS to support memory T cell longevity.  Lowering the 
glycolytic threshold of T effectors has been shown to improve memory T cell formation [135, 
136].  The data presented in Figure 15 indicate that LAG-3-deficient T cells exhibit enhanced 
aerobic glycolysis upon activation.  Together, these studies suggest that LAG-3-/- T cells, due to 
their highly glycolytic nature, may not transition to memory T cells as effectively as wildtype T 
cells.  Moreover, LAG-3 expression may serve as a metabolic regulatory mechanism to dampen 
glycolytic potential thereby ensuring efficient T effector contraction. 
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Preliminary in vivo studies were performed to address this question, where animals were 
immunized with ovalbumin and memory T cell function was assessed 30 days later (Appendix 
A).  Results indicated trends in reduced cellularity of draining lymph nodes in LAG-3-/- animals 
(Figure 30A), along with a lower frequency of memory T cells (CD62Lhi CD44hi) as compared to 
wildtype animals (Figure 30B; p<0.05).  Upon restimulation in vitro, wildtype memory T cells 
produced greater levels of IFNγ, suggesting a more robust memory response (Figure 30C).  
Repeating these experiments with animals receiving adoptive transfers of OT.II T cells may 
prove beneficial in that it would provide a more distinct population that could also be isolated by 
tetramer staining.  Future experiments would be necessary to further understand potential 
differences, and to also assess metabolic differences.  Van der Windt et al. has developed an in 
vitro method of generating both effector and memory T cells [128, 129], which could be used 
with wildtype and LAG-3-/- OT.II cells for Seahorse analysis.      
      
 
4.1.4 LAG-3 and its effect on T regulatory cell metabolism 
Some naturally occurring CD4+CD25+ T regulatory cells demonstrate increased LAG-3 
expression as compared to naïve, effector, and memory subsets [141].  Moreover, they have been 
shown to utilize LAG-3 as a mode of suppressing effector T cell responses [141, 177].  Studies 
examining the metabolic profile of T regulatory cells have indicated that like naïve and memory 
subsets, they rely predominantly on OXPHOS.  Specifically, they utilize fatty acid metabolism, 
driven by high levels of AMPK expression [391].  Both mTOR inhibition (by knockout or 
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rapamycin treatment) or AMPK activation (via metformin treatment) enhanced T regulatory cell 
differentiation as well [384, 392], further supporting a role for this pathway.   
Work from Huang et al. indicated that LAG-3-/- regulatory T cells proliferated to a 
greater extent than wildtypes, which is in line with our work and other previous work that LAG-
3 expression inhibits T cell proliferation [157].  Our studies would further suggest that LAG-3-
deficient T regulatory cells may demonstrate increased mitochondrial mass and metabolism, as a 
means of supporting increased proliferation.  This could prove beneficial in autoimmune settings 
where T regulatory cell numbers wane.  However, it would be important to also verify that 
bioenergetic differences due to LAG-3 loss do not interfere with suppressive capabilities.  In 
some instances, where LAG-3 is utilized to mediate suppression, LAG-3 blockade would not be 
advantageous as the ability to restrain T cell responses is likely more important than increasing 
Treg numbers.  Unless this can be done temporally to boost numbers, and then remove treatment 
to enable suppression.  Future studies would be necessary to further elucidate potential metabolic 
implications on T regulatory cells.   
4.2 REDOX MODULATION IN TYPE 1 DIABETES 
4.2.1 MnP as a mono-therapy in T1D 
Data from our laboratory have demonstrated that use of MnP as a mono-therapy appears 
insufficient for maintaining durable tolerance, as once treatment ceases, NOD females succumb 
to T1D [168].  Therefore, understanding its deficiencies is critical for adjunct therapy 
development.  From a metabolic standpoint, the AMPK/mTOR axis is one pathway by which T 
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cell anergy is achieved.  Zheng et al. showed that anergic T cells are also metabolically anergic 
and express high levels of active AMPK which maintain OXPHOS and quiescence [369].  
AMPK also results in mTOR inhibition, again inhibiting activation potential.  We have shown 
here that redox modulation via MnP results in dampening mTOR and enhancing AMPK 
activation (Figures 25,28).  It is possible that the degree of these events is insufficient for 
permanent modification of the T cell phenotype.  Since MnP-treated T cells are still capable of 
full activation following MnP cessation and do not undergo apoptosis, AMPK activation in this 
context may serve as a survival mechanism for treated CD4+ T cells by maintaining efficient 
OXPHOS. 
 Our data here also indicated that MnP-treated T cells still produced sufficient levels of 
IL-2; but, downstream signaling was interrupted (Figure 25).  IL-2 is known to be effective in 
reversing T cell anergy, and this may provide a mechanism for reversal of hyporesponsiveness 
during MnP termination.  Specifically, IL-2 signaling results in inhibition of the protein 
deacetylase Sirtuin-1 (Sirt-1), reversing T cell induced anergy [393].  As anergic T cells express 
higher levels of Sirt-1 as compared to activated effector T cells, we tried to examine Sirt-1 
expression in our model, but were unable to see any appreciable differences with and without 
MnP treatment.  It is also interesting in that Sirt-1 is a downstream target of AMPK [394], 
begging the question that while MnP enhances AMPK activation, it might not result in enhanced 
Sirt-1 activity; thereby, not inducing T cell anergy.  Further experiments involving an IL-2 
depletion antibody or further examining Sirt-1 expression and activity may help to clarify the 
limitations of MnP treatment.     
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4.2.2 Metformin and Rapamycin as combinatorial therapies with MnP 
Combinatorial therapies with MnP and other agents may aid in providing long-term T cell 
hyporesponsiveness.  For example, metformin, an AMPK activator, may be a viable option as it 
has been shown to maintain AMPK activation in autoreactive T cells, resulting in reduced 
disease.  Additionally, T regulatory cells, which are highly oxidative, rely on AMPK activation 
for maintenance of the population and enabling their suppressive capabilities.  Driving reduced T 
effector responses while also potentially enhancing T regulatory function, may provide greater 
protection from disease onset.  Metformin has also been shown to protect islet β cells and 
preserve their glucose sensitivity and insulin secretion, providing even greater therapeutic 
potential.  Rapamycin, an mTOR inhibitor, might also be considered a viable option.  While 
rapamycin has shown potential for modulating T cell responses and metabolism in various 
models, including T1D, it is well documented that it is toxic to β cells [361].  Unpublished work 
from our laboratory has indicated that MnP administration in combination with rapamycin, 
protects β cells from these toxic effects.  Consequently, as both MnP and rapamycin provide 
immune suppressive functions, this could be a viable dual therapy in T1D.  Further studies would 
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APPENDIX A 
INVESTIGATING THE ROLE OF LAG-3 IN MEMORY T CELL FORMATION 
Preliminary studies were performed to investigate if LAG-3 deficient CD4+ T cells capable of 
forming functional memory responses.  Studies were performed using wildtype and LAG-3-/- B6 
animals, where animals were immunized with whole ovalbumin in Complete Freund’s Adjuvant 
(OVA; 100ug per mouse) at the base of the tail.  30 days post-immunization, animals were 
sacrificed, and draining inguinal lymph nodes (dLN) were harvested and re-stimulated with 
whole OVA in vitro (25 ug).  IFNγ production was used to measure activation.  Cells were also 
stained for flow cytometry to distinguish naïve, effector, and memory T cell subsets.  Vβ5 
expression was used to further gate on OVA-specific T cells.  dLN from non-immunized mice 










































Figure 30. LAG-3 deficient CD4+ T cells demonstrate impaired memory T cell formation and functionality. 
A.  Absolute number of cells from draining inguinal lymph nodes (dLN) 30 days post-immunization with OVA.  B.  
Frequency of naïve, effector, and memory CD4+ T cells following immunization.  CD4+Vβ5+ T cells were gated on, 
and expression of CD62L and CD44 were used to delineate naïve, effector, and memory subsets.  C.  IFNγ ELISA 
results from in vitro recall assay.  Data points are indicative of individual animals, and significance was determined 
using a Student’s t test.  *=p<0.05.  
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